[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5517
1. Fullen DR, Zhu W, Thomas D, Su LD: hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol; 2005 Nov;32(10):680-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have yielded conflicting results on whether human telomerase RNA (hTER) expression differs in nevi, atypical nevi and melanomas using polymerase chain reaction-based telomeric repeat amplification protocol or in situ hybridization assays.
  • METHODS: Paraffin-embedded sections from 12 acquired nevi, seven dysplastic nevi, 11 Spitz nevi, eight primary invasive melanomas, and three metastatic melanomas were studied for staining intensity (0-3+) and percentage of labeled cells with anti-hTERT.
  • Spitz nevi tended to have weaker hTERT staining (mean = 1.7) compared with acquired nevi (mean = 2.2), dysplastic nevi (mean = 2.4), primary melanomas (mean = 2.4), or metastatic melanomas (mean = 3).
  • CONCLUSIONS: Although telomerase activity was weaker in Spitz nevi, there was overlap with other nevi and primary invasive melanomas in our small series.
  • Thus, hTERT expression does not appear to be a reliable adjunct to the histological diagnosis of primary melanocytic lesions.
  • [MeSH-major] DNA-Binding Proteins / analysis. Melanocytes / enzymology. Melanoma / enzymology. Nevus / chemistry. Nevus, Epithelioid and Spindle Cell / enzymology. Nevus, Pigmented / enzymology. Telomerase / analysis
  • [MeSH-minor] Cell Nucleus / chemistry. Diagnosis, Differential. Dysplastic Nevus Syndrome / diagnosis. Dysplastic Nevus Syndrome / enzymology. Dysplastic Nevus Syndrome / pathology. Humans. Immunohistochemistry. Paraffin Embedding. Reproducibility of Results. Skin / enzymology. Skin / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293180.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


2. Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP: Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol; 2005 Aug;141(8):998-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
  • OBJECTIVE: To determine the incidence of new, changed, and regressed nevi and melanomas in a cohort of patients at high risk for melanoma using baseline total body photography and dermatoscopy.
  • SETTING: Private practice rooms of 1 dermatologist in conjunction with a public hospital-based, multidisciplinary melanoma clinic in Victoria, Australia.
  • PATIENTS: A total of 309 patients who had at least 1 of the following risk factors for melanoma: personal history, family history, 100 or more nevi, or 4 or more dysplastic nevi.
  • MAIN OUTCOME MEASURES: Number of new, changed, and regressed nevi and melanomas detected and excised during the study interval.
  • RESULTS: The incidence of new, changed, and regressed nevi decreased with increasing age (P<.001), whereas the incidence of melanomas increased (P = .05).
  • The number of dysplastic nevi at baseline was positively associated with the incidence of changed nevi (P<.001) and melanomas (P = .03).
  • The development of melanoma in association with a preexisting nevus was not directly correlated with a change in a preexisting lesion monitored by baseline photography.
  • CONCLUSIONS: Nevi are dynamic, and only a small percentage of all new and changed melanocytic lesions are melanomas.
  • Patients younger than 50 years had a lower incidence of melanomas and a higher rate of new, changed, and regressed nevi when compared with patients older than 50 years.
  • [MeSH-major] Dermoscopy. Melanoma / pathology. Nevus / pathology. Photography. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Dysplastic Nevus Syndrome / pathology. Female. Humans. Male. Middle Aged. Nevus, Pigmented / pathology. Remission, Spontaneous. Risk Factors


3. Stephens C, Christen B, Fuchs T, Sundaram V, Watanabe K, Jenal U: Genetic analysis of a novel pathway for D-xylose metabolism in Caulobacter crescentus. J Bacteriol; 2007 Mar;189(5):2181-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic analysis of a novel pathway for D-xylose metabolism in Caulobacter crescentus.
  • Enzymes of the C. crescentus pathway, including an NAD(+)-dependent xylose dehydrogenase, are encoded in the xylose-inducible xylXABCD operon (CC0823-CC0819).

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4136-41 [11259647.001]
  • [Cites] Gene. 1993 Aug 16;130(1):155-6 [8344525.001]
  • [Cites] Nat Rev Genet. 2003 Apr;4(4):309-14 [12671661.001]
  • [Cites] Arch Microbiol. 2003 Aug;180(2):134-41 [12811467.001]
  • [Cites] J Bacteriol. 2004 Mar;186(5):1448-61 [14973021.001]
  • [Cites] J Bacteriol. 2004 Sep;186(18):6198-207 [15342590.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Oct 23;60(4):1433-9 [4423285.001]
  • [Cites] Microbios. 1976;16(65-66):219-26 [18652.001]
  • [Cites] J Biol Chem. 1982 Mar 25;257(6):2926-31 [7037773.001]
  • [Cites] Methods Enzymol. 1982;89 Pt D:226-8 [6755170.001]
  • [Cites] Adv Biochem Eng Biotechnol. 1983;27:1-32 [6437152.001]
  • [Cites] J Bacteriol. 1997 Feb;179(3):592-600 [9006009.001]
  • [Cites] Res Microbiol. 1996 Jul-Sep;147(6-7):448-55 [9084754.001]
  • [Cites] Microbiology. 1997 May;143 ( Pt 5):1639-48 [9168612.001]
  • [Cites] Arch Microbiol. 1999 Feb;171(3):189-97 [10201097.001]
  • [Cites] J Biol Chem. 1961 Mar;236:629-35 [13783864.001]
  • [Cites] Bacteriol Rev. 1964 Sep;28:231-95 [14220656.001]
  • [Cites] Biochem J. 1965 Apr;95:48-58 [14333567.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2612-23 [16326697.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):28876-88 [16835232.001]
  • [Cites] Appl Environ Microbiol. 1984 Jan;47(1):15-21 [6320721.001]
  • [Cites] J Biol Chem. 1987 Oct 15;262(29):13928-32 [2820984.001]
  • [Cites] J Bacteriol. 1990 Nov;172(11):6568-72 [2172217.001]
  • [Cites] Methods Enzymol. 1991;204:372-84 [1658564.001]
  • [Cites] Arch Microbiol. 1991;155(6):526-34 [1953294.001]
  • [Cites] Arch Microbiol. 1991;155(6):535-42 [1719948.001]
  • [Cites] Mol Gen Genet. 1991 Nov;230(1-2):161-9 [1660563.001]
  • [Cites] J Bacteriol. 2002 Apr;184(8):2155-66 [11914347.001]
  • (PMID = 17172333.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] A1TA934AKO / Xylose; B40ROO395Z / Arabinose; EC 1.1.- / Carbohydrate Dehydrogenases; EC 1.1.99.- / aldose dehydrogenase (pyrroloquinoline-quinone)
  • [Other-IDs] NLM/ PMC1855722
  •  go-up   go-down


Advertisement
4. Lam le H, Shimamura T, Ishiyama M, Ukeda H: Flow injection analysis of angiotensin I-converting enzyme inhibitory activity with enzymatic reactors. Talanta; 2009 Sep 15;79(4):1130-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the use of a new synthetic substrate, 3-hydroxybutyrylglycyl-glycyl-glycine (3HB-GGG), for the assay of ACE inhibitory activity has been confirmed.
  • Under the optimized conditions, 3HB-G was converted to 3HB, and then 3HB was oxidized by NAD(+) to form NADH.
  • The developed system successfully detected practical ACE inhibitors with a great sensitivity, high sampling frequency (10 samples h(-1)) and a durable stability of the enzymatic reactors.
  • [MeSH-minor] 3-Hydroxybutyric Acid / metabolism. Acetoacetates / metabolism. Amidohydrolases / chemistry. Amidohydrolases / metabolism. Biocatalysis. Enzymes, Immobilized / chemistry. Enzymes, Immobilized / metabolism. Hydrolysis. Hydroxybutyrate Dehydrogenase / chemistry. Hydroxybutyrate Dehydrogenase / metabolism. Hydroxybutyrates. Inhibitory Concentration 50. NAD / metabolism. Oligopeptides / metabolism. Oxidation-Reduction. Pseudomonas / enzymology. Spectrophotometry. Time Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615521.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-hydroxybutyrylglycyl-glycyl-glycine; 0 / Acetoacetates; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Enzymes, Immobilized; 0 / Hydroxybutyrates; 0 / Oligopeptides; 0U46U6E8UK / NAD; 4ZI204Y1MC / acetoacetic acid; EC 1.1.1.30 / Hydroxybutyrate Dehydrogenase; EC 3.4.15.1 / Peptidyl-Dipeptidase A; EC 3.5.- / Amidohydrolases; EC 3.5.1.14 / aminoacylase I; TZP1275679 / 3-Hydroxybutyric Acid
  •  go-up   go-down


5. Shimada K, Miyashiro Y, Nishio T: Characterization of in vitro metabolites of toad venom using high-performance liquid chromatography and liquid chromatography-mass spectrometry. Biomed Chromatogr; 2006 Dec;20(12):1321-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Marinobufagin was subjected to the enzyme reaction using the rat or human liver microsomal fraction together with NADPH and NAD, which produced 3-dehydromarinobufagin and 3-epimarinobufagin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 John Wiley & Sons, Ltd.
  • (PMID = 17080495.001).
  • [ISSN] 0269-3879
  • [Journal-full-title] Biomedical chromatography : BMC
  • [ISO-abbreviation] Biomed. Chromatogr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amphibian Venoms; 0 / Bufanolides; 0 / Sulfuric Acid Esters; 3K654P2M4J / bufogenin; 8A5D83Q4RW / Glucuronic Acid; L30U3VAH5C / bufotoxin
  •  go-up   go-down


6. St Hilaire C, Koupenova M, Carroll SH, Smith BD, Ravid K: TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun; 2008 Oct 24;375(3):292-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4.
  • Recently, an A(2B) adenosine receptor (A(2B)AR) knockout mouse illustrated that this receptor is a tissue protector, in that it inhibits VSMC proliferation and attenuates the inflammatory response following injury, including the release of TNF-alpha.
  • The effect of this cytokine is mimicked by its known downstream target, NAD(P)H oxidase 4 (Nox4).

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2000 Oct;14(13):2065-74 [11023991.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:775-87 [11264476.001]
  • [Cites] FEBS Lett. 2001 Sep 14;505(2):269-74 [11566189.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 1;31(11):1456-64 [11728818.001]
  • [Cites] Nature. 2001 Dec 20-27;414(6866):916-20 [11780065.001]
  • [Cites] Circulation. 2002 Mar 5;105(9):1135-43 [11877368.001]
  • [Cites] Life Sci. 2002 Sep 20;71(18):2083-103 [12204768.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):868-74 [12490960.001]
  • [Cites] Endothelium. 2002;9(4):263-71 [12572857.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Aug;285(2):R277-97 [12855411.001]
  • [Cites] Trends Immunol. 2004 Jan;25(1):33-9 [14698282.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1844-54 [14966267.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):181-9 [15039755.001]
  • [Cites] Front Biosci. 1996 Jul 1;1:d72-90 [9159214.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45935-41 [15322091.001]
  • [Cites] Jpn J Infect Dis. 2004 Oct;57(5):S28-9 [15507765.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Biochem J. 1993 Feb 15;290 ( Pt 1):41-9 [8439298.001]
  • [Cites] J Clin Invest. 1993 Sep;92(3):1564-71 [8397228.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):12-8 [8548411.001]
  • [Cites] Hypertension. 1996 Mar;27(3 Pt 2):786-93 [8613241.001]
  • [Cites] J Immunol. 1996 Nov 15;157(10):4634-40 [8906843.001]
  • [Cites] Kidney Int. 1997 Dec;52(6):1478-85 [9407493.001]
  • [Cites] Biochem J. 1998 Feb 1;329 ( Pt 3):653-7 [9445395.001]
  • [Cites] Microvasc Res. 1997 Nov;54(3):243-52 [9441895.001]
  • [Cites] Hypertension. 1998 Jan;31(1 Pt 2):516-21 [9453355.001]
  • [Cites] Microb Drug Resist. 1998 Spring;4(1):37-44 [9533723.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2596-606 [9564042.001]
  • [Cites] J Neurochem. 2004 Dec;91(5):1180-90 [15569261.001]
  • [Cites] Biochem Pharmacol. 2005 Mar 15;69(6):883-9 [15748700.001]
  • [Cites] Trends Immunol. 2005 Jun;26(6):299-304 [15922945.001]
  • [Cites] Cell Mol Life Sci. 2005 Nov;62(22):2647-57 [16322943.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):172-80 [16339914.001]
  • [Cites] J Cell Mol Med. 2006 Jan-Mar;10(1):231-9 [16563235.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1913-23 [16823489.001]
  • [Cites] Circulation. 2006 Oct 31;114(18):1923-32 [17043167.001]
  • [Cites] FASEB J. 2006 Nov;20(13):2242-50 [17077301.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):42-8 [17082491.001]
  • [Cites] Arch Biochem Biophys. 2007 Jan 15;457(2):134-41 [17166480.001]
  • [Cites] J Cell Biochem. 2008 Apr 15;103(6):1962-74 [17979185.001]
  • (PMID = 18647598.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL013262-260037; United States / NHLBI NIH HHS / HL / T32 HL007969; United States / NHLBI NIH HHS / HL / P01 HL013262; United States / NHLBI NIH HHS / HL / HL013262-260037; United States / NHLBI NIH HHS / HL / HL007969-03; United States / NHLBI NIH HHS / HL / T32 HL007969-03; United States / NHLBI NIH HHS / HL / HL13262
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Receptor, Adenosine A2A; 0 / Tumor Necrosis Factor-alpha; EC 1.6.- / Nox4 protein, mouse; EC 1.6.3.1 / NADPH Oxidase
  • [Other-IDs] NLM/ NIHMS70651; NLM/ PMC2583397
  •  go-up   go-down


7. Srivastava SK, Dube D, Kukshal V, Jha AK, Hajela K, Ramachandran R: NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor. Proteins; 2007 Oct 1;69(1):97-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor.
  • Mycobacterium tuberculosis codes for an essential NAD+-dependent DNA ligase (MtuLigA) which is a novel, validated, and attractive drug target.
  • We also report the identification, through virtual screening, of a novel N-substituted tetracyclic indole that competes with NAD+ and inhibits the enzyme with IC50 in the low muM range.
  • In silico ligand-docking studies suggest that the exquisite specificity of the inhibitor arises on account of its mimicking the interactions of NAD+ with MtuLigA.

  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc.
  • (PMID = 17557328.001).
  • [ISSN] 1097-0134
  • [Journal-full-title] Proteins
  • [ISO-abbreviation] Proteins
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Indoles; EC 6.5.1.- / DNA Ligases; EC 6.5.1.2 / DNA ligase (NAD)
  •  go-up   go-down


8. Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I, Soucek P: NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors. Pharmacogenet Genomics; 2009 Jul;19(7):505-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors.
  • OBJECTIVE: The aim of this study was to further clarify the recently reported role of NAD(P)H:quinone oxidoreductase 1 (NQO1) as a strong prognostic and predictive factor in breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Gene Expression Regulation, Neoplastic. NAD(P)H Dehydrogenase (Quinone) / genetics. Polymorphism, Single Nucleotide / genetics. Proline / genetics. Serine / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827856191 for PMID:19494791 [PharmGKB] .
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19494791.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 452VLY9402 / Serine; 9DLQ4CIU6V / Proline; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


9. Lee SO, Chang YC, Whang K, Kim CH, Lee IS: Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells. Cardiovasc Res; 2007 Nov 1;76(2):331-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells.
  • OBJECTIVES: In a preliminary study, NAD(P)H:quinone oxidoreductase 1 (NQO1) was found to be highly expressed in cultured human aortic smooth muscle cells (HASMC) and dicumarol, a NQO1 inhibitor and a coumarin-derived natural anticoagulant, suppressed tumor necrosis factor (TNF)-alpha-induced HASMC migration.
  • [MeSH-major] Muscle, Smooth, Vascular / drug effects. Myocytes, Smooth Muscle / drug effects. NAD(P)H Dehydrogenase (Quinone) / physiology. Tumor Necrosis Factor-alpha / pharmacology

  • Hazardous Substances Data Bank. DICUMAROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17669387.001).
  • [ISSN] 0008-6363
  • [Journal-full-title] Cardiovascular research
  • [ISO-abbreviation] Cardiovasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Transcription Factor AP-1; 0 / Tumor Necrosis Factor-alpha; 7QID3E7BG7 / Dicumarol; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


10. de Sousa NC, de Rezende AA, da Silva RM, Guterres ZR, Graf U, Kerr WE, Spanó MA: Modulatory effects of Tabebuia impetiginosa (Lamiales, Bignoniaceae) on doxorubicin-induced somatic mutation and recombination in Drosophila melanogaster. Genet Mol Biol; 2009 Apr;32(2):382-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They induce apoptosis by generating oxygen-reactive species, thereby inhibiting topoisomerases (I and II) or inducing other enzymes dependent on NAD(P)H:quinone oxidoreductase 1, thus affecting cell cycle checkpoints.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phytochemistry. 2005 Mar;66(5):589-97 [15721952.001]
  • [Cites] Mutat Res. 2006 Sep 5;607(2):225-30 [16777474.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Dec 1;17(23):6417-20 [17950604.001]
  • [Cites] Food Chem Toxicol. 2008 Mar;46(3):1103-10 [18160198.001]
  • [Cites] Mutat Res. 1990 Jul;244(3):201-8 [2114542.001]
  • [Cites] Mutat Res. 1989 Jun;216(3):179-87 [2499781.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2006 Jan;54(1):14-20 [16394542.001]
  • [Cites] Environ Mol Mutagen. 2003;41(4):293-9 [12717784.001]
  • [Cites] Mutagenesis. 2001 Sep;16(5):385-94 [11507237.001]
  • [Cites] Environ Mol Mutagen. 2000;36(3):195-200 [11044900.001]
  • [Cites] Phytochemistry. 2000 Apr;53(8):869-72 [10820794.001]
  • [Cites] Mutat Res. 2005 Aug 1;585(1-2):147-55 [16005256.001]
  • [Cites] Phytochemistry. 2004 Jul;65(13):2003-11 [15280007.001]
  • [Cites] Life Sci. 2004 Mar 12;74(17):2157-84 [14969719.001]
  • [Cites] Life Sci. 2004 Jan 9;74(8):935-68 [14672753.001]
  • [Cites] Mutat Res. 1992 Feb;271(1):59-67 [1371830.001]
  • [Cites] Genetics. 1977 Dec;87(4):685-97 [414959.001]
  • [Cites] Mutat Res. 1998 Jun 18;402(1-2):203-9 [9729134.001]
  • [Cites] J Ethnopharmacol. 1993 Jun;39(2):119-28 [8412245.001]
  • [Cites] Mutagenesis. 1994 Jul;9(4):383-6 [7968582.001]
  • [Cites] Mutat Res. 1995 Apr;334(2):247-58 [7885379.001]
  • [Cites] Environ Mutagen. 1984;6(2):153-88 [6423380.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):460-72 [6293697.001]
  • [Cites] Mutat Res. 1988 Aug;203(4):297-308 [3136327.001]
  • [Cites] Mutat Res. 1989 Apr;222(4):359-73 [2495439.001]
  • [Cites] Drug Metab Dispos. 2008 Apr;36(4):753-8 [18227145.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49 [17594094.001]
  • [Cites] Mutat Res. 2007 Jan 10;626(1-2):1-3 [17141555.001]
  • [Cites] IARC Sci Publ. 1999;(146):427-70 [10353398.001]
  • [Cites] J Nat Prod. 1999 Aug;62(8):1134-6 [10479319.001]
  • [Cites] Mutat Res. 1999 Aug 18;444(2):355-65 [10521675.001]
  • [Cites] J Antimicrob Chemother. 2005 Dec;56(6):1034-41 [16269551.001]
  • [Cites] J Ethnopharmacol. 2006 Apr 21;105(1-2):255-62 [16359837.001]
  • [Cites] Mutat Res. 2003 Aug 5;539(1-2):167-75 [12948825.001]
  • (PMID = 21637695.001).
  • [ISSN] 1415-4757
  • [Journal-full-title] Genetics and molecular biology
  • [ISO-abbreviation] Genet. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC3036921
  • [Keywords] NOTNLM ; genotoxicity / somatic mutation and recombination test - SMART / synergistic effect / toxicity / wing spot test
  •  go-up   go-down


11. Niemiec P, Zak I, Emich-Widera E, Balcerzyk A, Kopyta I, Nowak T, Wendorff J, Pałatyńska K, Kaciński M, Pienczk-Ręcławowicz K, Pilarska E: The C242T polymorphism of the gene encoding cytochrome b-245 alpha is not associated with paediatric ischaemic stroke: family-based and case-control study. Neurol Neurochir Pol; 2010 Sep-Oct;44(5):453-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytochrome b-245 alpha gene (CYBA) encodes cytochrome b-245 alpha light chain (p22phox peptide), a critical element of NAD(P)H oxidases, the most important source of superoxide anion in the cerebral arteries.

  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082491.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 1.6.3.1 / CYBA protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


12. Pacher P, Szabo C: Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol; 2008 Jul;173(1):2-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARP overactivation depletes its substrate NAD(+), slowing the rate of glycolysis, electron transport, and ATP formation, eventually leading to functional impairment or death of cells, as well as up-regulation of various proinflammatory pathways.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 1999 Sep;160(3):1031-4 [10471637.001]
  • [Cites] Oncogene. 2007 Dec 10;26(56):7816-24 [18066095.001]
  • [Cites] Int J Cardiol. 2008 Jan 24;123(3):366-8 [17689746.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1197-208 [18025084.001]
  • [Cites] J Neurol. 2008 Jan;255(1):94-8 [18080850.001]
  • [Cites] Science. 2008 Feb 8;319(5864):819-21 [18258916.001]
  • [Cites] BMC Bioinformatics. 2007;8:483 [18093328.001]
  • [Cites] Int J Mol Med. 2008 Jul;22(1):113-8 [18575783.001]
  • [Cites] J Neurosurg. 2003 Jul;99(1):125-30 [12854754.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jan;163(1):166-72 [11208643.001]
  • [Cites] Circulation. 2001 Jul 10;104(2):174-80 [11447082.001]
  • [Cites] Diabetologia. 2001 Jul;44(7):834-8 [11508267.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):571-6 [11515899.001]
  • [Cites] Circulation. 2001 Sep 18;104(12 Suppl 1):I336-43 [11568079.001]
  • [Cites] J Heart Lung Transplant. 2003 Sep;22(9):1028-36 [12957613.001]
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Dec;126(6):1813-21 [14688692.001]
  • [Cites] J Autoimmun. 2004 Feb;22(1):87-94 [14709417.001]
  • [Cites] Neurology. 2004 Jan 27;62(2):319-22 [14745081.001]
  • [Cites] Trends Pharmacol Sci. 2004 May;25(5):259-64 [15120492.001]
  • [Cites] Crit Care Med. 2006 Apr;34(4):1073-9 [16484919.001]
  • [Cites] J Vasc Surg. 2006 Apr;43(4):760-70; discussion 770-1 [16616233.001]
  • [Cites] Free Radic Biol Med. 2006 Apr 15;40(8):1454-65 [16631535.001]
  • [Cites] Rheumatology (Oxford). 2006 Jun;45(6):711-7 [16461442.001]
  • [Cites] Trends Biochem Sci. 2006 Jun;31(6):309-11 [16679020.001]
  • [Cites] Circulation. 2006 Jul 4;114(1 Suppl):I257-63 [16820582.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28 [16829982.001]
  • [Cites] Curr Pharm Des. 2006;12(23):2903-10 [16918420.001]
  • [Cites] Free Radic Biol Med. 2006 Nov 1;41(9):1384-91 [17023265.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 17;350(2):352-7 [17007818.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2006 Nov;91(6):F429-33 [16835259.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):1056-62 [17046715.001]
  • [Cites] Arthritis Rheum. 2001 Dec;44(12):2909-21 [11762952.001]
  • [Cites] Diabetes Care. 2002 Aug;25(8):1439-43 [12145247.001]
  • [Cites] Circulation. 2002 Aug 20;106(8):927-32 [12186795.001]
  • [Cites] Diabetes. 2002 Sep;51(9):2817-25 [12196476.001]
  • [Cites] Basic Res Cardiol. 2002 Sep;97(5):409-15 [12200641.001]
  • [Cites] Pharmacol Rev. 2002 Sep;54(3):375-429 [12223530.001]
  • [Cites] Br J Pharmacol. 2003 Feb;138(4):532-43 [12598407.001]
  • [Cites] Arthritis Rheum. 2003 Mar;48(3):638-41 [12632415.001]
  • [Cites] Toxicol Lett. 2003 Apr 11;140-141:105-12 [12676456.001]
  • [Cites] J Neurochem. 2003 May;85(3):697-708 [12694396.001]
  • [Cites] Free Radic Biol Med. 2003 Jul 15;35(2):140-8 [12853070.001]
  • [Cites] Crit Rev Oral Biol Med. 2004;15(3):156-64 [15187033.001]
  • [Cites] Science. 2004 Jun 18;304(5678):1820-2 [15205535.001]
  • [Cites] Neuroreport. 2004 Aug 6;15(11):1715-8 [15257133.001]
  • [Cites] J Heart Lung Transplant. 2004 Jun;23(6):723-8 [15366433.001]
  • [Cites] Mol Med. 2004 Jan-Jun;10(1-6):28-35 [15502880.001]
  • [Cites] Clin Exp Immunol. 1979 Apr;36(1):151-64 [313859.001]
  • [Cites] Arthritis Rheum. 1989 Aug;32(8):1045-9 [2765003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4 [2154753.001]
  • [Cites] Autoimmunity. 1990;6(3):203-9 [2129778.001]
  • [Cites] Science. 1994 Feb 4;263(5147):687-9 [8080500.001]
  • [Cites] Clin Immunol Immunopathol. 1995 Dec;77(3):349-57 [7586746.001]
  • [Cites] J Immunol. 1996 Jan 1;156(1):350-8 [8598485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1753-8 [8700830.001]
  • [Cites] Mol Cell Biochem. 1996 Oct-Nov;163-164:261-75 [8974066.001]
  • [Cites] Crit Care Med. 1997 May;25(5):812-9 [9187601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3867-72 [9520459.001]
  • [Cites] Transplantation. 1998 Mar 27;65(6):804-12 [9539092.001]
  • [Cites] Circulation. 1998 Jun 16;97(23):2338-45 [9639378.001]
  • [Cites] Trends Pharmacol Sci. 1998 Jul;19(7):287-98 [9703762.001]
  • [Cites] Immunology. 1998 Jul;94(3):345-55 [9767416.001]
  • [Cites] Brain. 1999 Feb;122 ( Pt 2):247-53 [10071053.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):98-103 [10215997.001]
  • [Cites] Trends Pharmacol Sci. 2006 Dec;27(12):626-30 [17055069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18314-9 [17116881.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Feb;36(2):152-7 [17023686.001]
  • [Cites] Mol Med. 2006 Sep-Oct;12(9-10):221-8 [17225870.001]
  • [Cites] J Cell Biochem. 2007 Feb 1;100(2):385-401 [16924674.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):315-424 [17237348.001]
  • [Cites] Clin Nephrol. 2002 Aug;58(2):103-10 [12227681.001]
  • [Cites] Circulation. 2002 Nov 19;106(21):2680-6 [12438293.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Jan;62(1):88-103 [12528821.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):163-9 [12531868.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jan;125(1):178-83 [12539002.001]
  • [Cites] Crit Care Med. 2003 Feb;31(2):353-8 [12576936.001]
  • [Cites] Nat Rev Drug Discov. 2007 Aug;6(8):662-80 [17667957.001]
  • [Cites] Crit Care Med. 1999 Sep;27(9):1738-44 [10507592.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H486-96 [15374823.001]
  • [Cites] Curr Med Chem. 2005;12(3):267-75 [15723618.001]
  • [Cites] Circulation. 2005 Mar 1;111(8):988-95 [15710754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3483-8 [15728348.001]
  • [Cites] FASEB J. 2005 Mar;19(3):401-3 [15611153.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):179-94 [15857303.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):421-40 [15864271.001]
  • [Cites] Pharmacol Res. 2005 Jul;52(1):15-24 [15911330.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):55-66 [10736067.001]
  • [Cites] Circ Res. 2000 Dec 8;87(12):1123-32 [11110769.001]
  • [Cites] Br J Pharmacol. 2001 Feb;132(4):815-27 [11181422.001]
  • [Cites] Trends Pharmacol Sci. 2005 Jun;26(6):302-10 [15925705.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jul;314(1):53-60 [15784653.001]
  • [Cites] J Neurosci Res. 2005 Jul 15;81(2):190-8 [15931673.001]
  • [Cites] Cardiovasc Res. 2005 Aug 1;67(2):225-33 [16005301.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):221-9 [16026319.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):231-46 [16026320.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):267-83 [16026323.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):285-91 [16026324.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):293-9 [16026325.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1711-7 [16291064.001]
  • [Cites] Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1568-80 [16356120.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):43121-30 [16207712.001]
  • [Cites] Transplant Proc. 2005 Nov;37(9):3684-7 [16386505.001]
  • [Cites] Hypertens Res. 2005 Oct;28(10):779-86 [16471171.001]
  • [Cites] Curr Opin Pharmacol. 2006 Apr;6(2):136-41 [16483848.001]
  • [Cites] Curr Opin Cell Biol. 2006 Apr;18(2):145-51 [16516457.001]
  • [Cites] Thromb Haemost. 2006 Jan;95(1):43-8 [16543960.001]
  • [Cites] Mol Med. 2006 Jul-Aug;12(7-8):143-52 [17088946.001]
  • [Cites] Mech Ageing Dev. 2007 Feb;128(2):173-81 [17116320.001]
  • [Cites] Dement Geriatr Cogn Disord. 2007;23(4):215-8 [17290104.001]
  • [Cites] Neuroscience. 2007 Apr 14;145(4):1267-72 [17084037.001]
  • [Cites] Curr Med Chem. 2007;14(11):1179-87 [17504138.001]
  • [Cites] Clin Exp Rheumatol. 2007 Mar-Apr;25(2):281-6 [17543154.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(9):1673-84 [17540609.001]
  • [Cites] Free Radic Biol Med. 2007 Sep 1;43(5):763-80 [17664140.001]
  • [Cites] Pharmacol Res. 2005 Jul;52(1):109-18 [15911339.001]
  • [Cites] Mol Cell Biochem. 2007 Sep;303(1-2):19-25 [17396231.001]
  • [Cites] Ann N Y Acad Sci. 2007 Aug;1109:338-44 [17785323.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2124-33 [17714938.001]
  • [Cites] Transplant Proc. 2007 Sep;39(7):2099-101 [17889105.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):515-23 [17896912.001]
  • [Cites] Apoptosis. 2007 Nov;12(11):2037-49 [17828454.001]
  • [Cites] Cardiovasc Drug Rev. 2007 Fall;25(3):235-60 [17919258.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7475-85 [17785446.001]
  • [Cites] Front Biosci. 2008;13:3046-82 [17981777.001]
  • [Cites] Int J Mol Med. 2007 Dec;20(6):783-92 [17982684.001]
  • [Cites] Trends Pharmacol Sci. 2007 Nov;28(11):556-60 [17950909.001]
  • [Cites] Circulation. 2007 Nov 13;116(20):2315-24 [17967979.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Dec;8(12):1051-6 [18058575.001]
  • (PMID = 18535182.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060915; United States / Intramural NIH HHS / / Z01 AA000375-02; United States / Intramural NIH HHS / / Z99 AA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oxidants; 14691-52-2 / Peroxynitrous Acid; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 130
  • [Other-IDs] NLM/ PMC2438280
  •  go-up   go-down


13. Kim SY, Gul R, Rah SY, Kim SH, Park SK, Im MJ, Kwon HJ, Kim UH: Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells. Am J Physiol Renal Physiol; 2008 Apr;294(4):F982-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ADP-ribosyl cyclase (ADPR-cyclase) produces a Ca(2+)-mobilizing second messenger cyclic ADP-ribose (cADPR) from NAD(+).
  • Treatment of MMCs with ANG II induced an increase in intracellular Ca(2+) concentrations through a transient Ca(2+) release via an inositol 1,4,5-trisphosphate receptor and a sustained Ca(2+) influx via L-type Ca(2+) channels.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272599.001).
  • [ISSN] 1931-857X
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Pyridines; 0 / Vasoconstrictor Agents; 11128-99-7 / Angiotensin II; 119340-53-3 / Cyclic ADP-Ribose; 130663-39-7 / PD 123319; EC 3.2.2.5 / ADP-ribosyl Cyclase; SY7Q814VUP / Calcium
  •  go-up   go-down


14. Ogawa T, Ueda Y, Yoshimura K, Shigeoka S: Comprehensive analysis of cytosolic Nudix hydrolases in Arabidopsis thaliana. J Biol Chem; 2005 Jul 1;280(26):25277-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nudix hydrolases are a family of proteins that catalyze the hydrolysis of a variety of nucleoside diphosphate derivatives.
  • These findings suggest that most cytosolic AtNUDTs may substantially function in the sanitization of potentially hazardous ADP-ribose and the regulation of the cellular NADH/NAD(+) ratio in plant cells.
  • On the other hand, the AtNUDT1 protein had the ability to hydrolyze 8-oxo-dGTP with a K(m) value of 6.8 mum and completely suppress the increased frequency of spontaneous mutations in the Escherichia coli mutT(-) strain, indicating that AtNUDT1 is a functional homologue of E. coli MutT in A. thaliana and is involved in the prevention of spontaneous mutation.
  • [MeSH-minor] Adenosine Diphosphate Ribose / chemistry. Amino Acid Motifs. Amino Acid Sequence. Catalysis. Chloroplasts / metabolism. Chromatography, High Pressure Liquid. Deoxyguanine Nucleotides / chemistry. Electrophoresis, Polyacrylamide Gel. Escherichia coli / metabolism. Escherichia coli Proteins / chemistry. Genetic Complementation Test. Humans. Hydrolysis. Kinetics. Molecular Sequence Data. Multigene Family. Mutation. Phosphoric Monoester Hydrolases / chemistry. Plasmids / metabolism. Protein Binding. Recombinant Proteins / chemistry. Saccharomyces cerevisiae / metabolism. Sequence Homology, Amino Acid. Substrate Specificity

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878881.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Deoxyguanine Nucleotides; 0 / Escherichia coli Proteins; 0 / Recombinant Proteins; 139307-94-1 / 8-oxodeoxyguanosine triphosphate; 20762-30-5 / Adenosine Diphosphate Ribose; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.6.1.- / NUDT1 protein, Arabidopsis; EC 3.6.1.- / Pyrophosphatases; EC 3.6.1.- / mutT protein, E coli; EC 3.6.1.9 / nucleotide pyrophosphatase
  •  go-up   go-down


15. Guttikonda SK, Trupti J, Bisht NC, Chen H, An YQ, Pandey S, Xu D, Yu O: Whole genome co-expression analysis of soybean cytochrome P450 genes identifies nodulation-specific P450 monooxygenases. BMC Plant Biol; 2010;10:243
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cytochrome P450 monooxygenases (P450s) catalyze oxidation of various substrates using oxygen and NAD(P)H.
  • The recent availability of the soybean genome sequence allows us to identify and analyze soybean putative P450s at a genome scale.
  • The tissue-specific expression patterns of these P450 genes were analyzed and the expression of a representative set of genes were confirmed by qRT-PCR.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plant Mol Biol. 2003 Dec;53(6):733-43 [15082922.001]
  • [Cites] Plant Physiol. 2003 Sep;133(1):63-72 [12970475.001]
  • [Cites] Pharmacogenetics. 1996 Feb;6(1):1-42 [8845856.001]
  • [Cites] Plant Mol Biol. 1996 May;31(2):323-35 [8756596.001]
  • [Cites] Drug Metabol Drug Interact. 1995;12(3-4):189-206 [8820852.001]
  • [Cites] Mol Gen Genet. 1998 May;258(4):315-22 [9648734.001]
  • [Cites] Plant Physiol. 1998 Aug;117(4):1393-400 [9701595.001]
  • [Cites] Arch Biochem Biophys. 1999 Sep 1;369(1):1-10 [10462435.001]
  • [Cites] J Am Chem Soc. 2005 Sep 14;127(36):12709-16 [16144421.001]
  • [Cites] Annu Rev Plant Biol. 2006;57:335-60 [16669765.001]
  • [Cites] Plant Physiol. 2006 May;141(1):121-34 [16531481.001]
  • [Cites] Methods Mol Biol. 2006;320:1-10 [16719369.001]
  • [Cites] Plant J. 2006 Oct;48(2):261-73 [17018035.001]
  • [Cites] Plant Cell Physiol. 2007 Mar;48(3):381-90 [17251202.001]
  • [Cites] Planta. 2007 Jun;226(1):109-23 [17273868.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W678-82 [17483516.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] BMC Plant Biol. 2008;8:47 [18433503.001]
  • [Cites] Science. 2009 Sep 25;325(5948):1688-92 [19779199.001]
  • [Cites] Plant Physiol. 2009 Oct;151(2):574-89 [19700560.001]
  • [Cites] Plant Physiol. 2009 Nov;151(3):1167-74 [19605552.001]
  • [Cites] Phytochemistry. 2009 Dec;70(17-18):1940-7 [19818975.001]
  • [Cites] Nucleic Acids Res. 2010 Jan;38(Database issue):D211-22 [19920124.001]
  • [Cites] Nature. 2010 Jan 14;463(7278):178-83 [20075913.001]
  • [Cites] Plant Physiol. 2010 Feb;152(2):541-52 [19933387.001]
  • [Cites] Plant J. 2010 Jul 1;63(1):86-99 [20408999.001]
  • [Cites] BMC Plant Biol. 2010;10:160 [20687943.001]
  • [Cites] Plant Physiol. 1999 Nov;121(3):821-8 [10557230.001]
  • [Cites] Nat Biotechnol. 2000 Feb;18(2):208-12 [10657130.001]
  • [Cites] Mol Cell. 2000 Jan;5(1):121-31 [10678174.001]
  • [Cites] DNA Cell Biol. 2000 May;19(5):307-17 [10855798.001]
  • [Cites] FEBS Lett. 2000 Sep 15;481(2):183-8 [10996320.001]
  • [Cites] Trends Plant Sci. 2000 Mar;5(3):116-23 [10707077.001]
  • [Cites] Arch Biochem Biophys. 2001 Feb 15;386(2):281-9 [11368353.001]
  • [Cites] Cell. 2001 Jun 1;105(5):625-36 [11389832.001]
  • [Cites] Curr Opin Plant Biol. 2002 Jun;5(3):230-6 [11960741.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46051-8 [12351632.001]
  • [Cites] Adv Ther. 2003 Jan-Feb;20(1):50-78 [12772818.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] Plant Mol Biol. 2004 Mar;54(5):623-39 [15356384.001]
  • (PMID = 21062474.001).
  • [ISSN] 1471-2229
  • [Journal-full-title] BMC plant biology
  • [ISO-abbreviation] BMC Plant Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Plant Proteins; 0 / Soybean Proteins; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.- / Mixed Function Oxygenases
  • [Other-IDs] NLM/ PMC3095325
  •  go-up   go-down


16. Massi G, Vellone VG, Pagliarello C, Fabrizi G: Plantar melanoma that mimics melanocytic nevi: a report of 4 cases with lymph node metastases and with review of positive and negative controls. Am J Dermatopathol; 2009 Apr;31(2):117-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plantar melanoma that mimics melanocytic nevi: a report of 4 cases with lymph node metastases and with review of positive and negative controls.
  • We report 4 cases of melanoma localized on the sole with some striking histological similarities to the compound nevi.
  • One case showed inguinal lymph node metastases after a diagnosis of compound nevus made 5 years earlier.
  • The other 3 cases were sent to us in consultation as suspected plantar lesions; a diagnosis of melanoma mimicking compound nevus was proposed: the sentinel lymph node technique was accordingly performed and resulted positive.
  • These 4 index cases were compared with 26 cases of ordinary plantar melanoma and with 117 cases of benign compound plantar nevi.
  • Histologically, the similarity of areas of these 4 cases of plantar melanoma to compound plantar nevi (namely Miescher, Clark, or acral lentiginous nevus) is so close that it may prove misleading in the diagnostic pathway.
  • In such cases, an erroneous diagnosis of benign lesion may be made.
  • The correct diagnosis of melanoma can, however, be done by combining the clinical and pathological findings.
  • In fact, this deceptive form of melanoma mimicking a compound nevus is characterized by patients' advanced age (>45 years), large lateral diameters (>10 mm), and significant depth of the lesion (>1 mm).
  • In our 4 cases, such features were combined with one or more of the following histological clues: lentiginous (ie, continuous) proliferation of enlarged and hyperchromatic melanocytes aligned in single units at the dermoepidermal junction; extensive eccrine duct melanocytic infiltration; dermal melanocytes with slight nuclear enlargement, nuclear membrane thickening and folding, and conspicuous central nucleoli; and cellular pleomorphism of the epidermal and dermal component.
  • In conclusion, a small group of plantar melanoma has striking similarities with compound nevi.
  • Only the correlation of clinical data (old age of the patient and large size of the lesion) with subtle architectural and cytological alterations (depth of the lesion, lentiginous melanocytic epidermal and eccrine proliferation, and cellular alteration and mitoses) allows a correct diagnosis.
  • [MeSH-major] Dermis / pathology. Melanoma / secondary. Nevus, Pigmented / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318796.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hong S, Brass A, Seman M, Haag F, Koch-Nolte F, Dubyak GR: Lipopolysaccharide, IFN-gamma, and IFN-beta induce expression of the thiol-sensitive ART2.1 Ecto-ADP-ribosyltransferase in murine macrophages. J Immunol; 2007 Nov 1;179(9):6215-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nicotinamide adenosine dinucleotide (NAD) can act as a modulator of multiple immune and inflammatory responses when released into extracellular compartments.
  • These actions of extracellular NAD are largely mediated by a family of mammalian ecto-ADP-ribosyltransferases (ARTs) that covalently modify target extracellular or cell surface proteins by transferring ADP-ribose to arginine or cysteine residues.
  • Collectively, these studies identify ART2.1 as a new candidate for linking autocrine/paracrine activation of inflammatory macrophages to the release of NAD, a critical intracellular metabolite.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947697.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM36387
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Sulfhydryl Compounds; 77238-31-4 / Interferon-beta; 82115-62-6 / Interferon-gamma; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / Art2a protein, mouse; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


18. Kurtasova LM, Golovanova AE, Savchenko AA: Enzymatic status of blood lymphocytes in young children with Epstein-Barr virus infection. Bull Exp Biol Med; 2010 Sep;149(3):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activities of NAD(PH)-dependent dehydrogenases in peripheral blood lymphocytes were studied in children aged 1-3 years in the dynamics of the disease caused by Epstein-Barr virus.

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21246096.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M; EC 1.6.- / NADH, NADPH Oxidoreductases
  •  go-up   go-down


19. Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, Diwan AH: Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer; 2006 Mar 1;106(5):1123-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, its diagnostic value in differentiating melanomas from nevi has not yet been examined.
  • METHODS: Tissue microarray blocks were constructed with paraffin-fixed tissue of 19 nevi, 18 dysplastic nevi, 24 malignant melanomas, and 31 metastatic melanomas.
  • Nuclear immunoreactivity for survivin (i.e., > or = 25% of cells exhibiting and/or at least moderately intense staining) was seen in a subset of melanomas but not in nevi or dysplastic nevi (P < 0.05).
  • These data may underscore the importance of nuclear survivin in progression to melanoma and may prove useful in the differential diagnosis of melanoma versus nevus.
  • [MeSH-major] Melanoma / genetics. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Skin Neoplasms / genetics
  • [MeSH-minor] Cell Nucleus / chemistry. Cell Survival. Diagnosis, Differential. Disease Progression. Gene Expression Profiling. Humans. Inhibitor of Apoptosis Proteins. Nevus / diagnosis. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456815.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Kobilková J, Jirásek JE, Jedlicková J, Benešová O, Mašata J: [Prevention of the invasion of malignant cells of gynecologic tumors during surgery]. Ceska Gynekol; 2010 Dec;75(6):553-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During gynecologic surgery of a choriocarcinoma and of an ovarian carcinoma Luksch and Cernoch prooved trace of malignant cells within the blood circulation related to the manipulation of tumors during surgery.
  • CONCLUSION: Although the members are small, there is doubt, that the ligation of oviducts and hypogastric vessels prior radical surgeries in patients affected by malignant gynecologic tumors substantially reduces metastazing of malignant cells nad improve the five years survival of surgically treated patients with gynecologic malignant tumors.


21. Medina M: Structural and mechanistic aspects of flavoproteins: photosynthetic electron transfer from photosystem I to NADP+. FEBS J; 2009 Aug;276(15):3942-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to their role in photosynthesis, flavodoxin and ferredoxin-NADP(+) reductase are ubiquitous flavoenzymes that deliver NAD(P)H or low midpoint potential one-electron donors to redox-based metabolisms in plastids, mitochondria and bacteria.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19583765.001).
  • [ISSN] 1742-4658
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ferredoxins; 0 / Flavoproteins; 0 / Photosystem I Protein Complex; 53-59-8 / NADP
  • [Number-of-references] 155
  •  go-up   go-down


22. Hashimoto Y, Ookuma S, Nishida E: Lifespan extension by suppression of autophagy genes in Caenorhabditis elegans. Genes Cells; 2009 Jun;14(6):717-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, our analysis suggests that the lifespan extension, which is induced by RNAi of unc-51, bec-1 or atg-9 after development, does not require the transcription factor daf-16, the NAD(+)-dependent protein deacetylase sir-2.1 or the genes related to mitochondrial functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469880.001).
  • [ISSN] 1365-2443
  • [Journal-full-title] Genes to cells : devoted to molecular & cellular mechanisms
  • [ISO-abbreviation] Genes Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins
  •  go-up   go-down


23. Merrell MD, Augustine LM, Slitt AL, Cherrington NJ: Induction of drug metabolism enzymes and transporters by oltipraz in rats. J Biochem Mol Toxicol; 2008 Mar-Apr;22(2):128-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, OPZ induced microsomal epoxide hydrolase, NAD(P)H quinone oxidoreductase, and Cyp3a1/23 equally in both genders, indicating a CAR-independent mechanism of induction of these genes.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley Periodicals, Inc.
  • (PMID = 18418891.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007091; United States / NIEHS NIH HHS / ES / ES011646; United States / NIEHS NIH HHS / ES / F32 ES011239; United States / NIEHS NIH HHS / ES / F32 ES011239-01; United States / NIEHS NIH HHS / ES / ES006694; United States / NIDDK NIH HHS / DK / R01 DK068039; United States / NIEHS NIH HHS / ES / K22 ES011646; United States / NIEHS NIH HHS / ES / F32 ES011239-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Pharmaceutical Preparations; 0 / Pyrazines; 6N510JUL1Y / oltipraz; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, rat
  •  go-up   go-down


24. Yoon HY, Kang NI, Lee HK, Jang KY, Park JW, Park BH: Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol; 2008 Jun 1;75(11):2214-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase 2 enzymes such as heme oxygenase-1, NAD(P)H: quinone oxidoreductase 1, glutathione reductase, and glutathione peroxidase participate in adaptive and protective responses to oxidative stress and various inflammatory stimuli.

  • Hazardous Substances Data Bank. OXYGEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407246.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isothiocyanates; 0 / NF-E2-Related Factor 2; 0 / Thiocyanates; 4478-93-7 / sulforafan; S88TT14065 / Oxygen
  •  go-up   go-down


25. Roldán MD, Pérez-Reinado E, Castillo F, Moreno-Vivián C: Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev; 2008 May;32(3):474-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bacterial nitroreductases are flavoenzymes that catalyze the NAD(P)H-dependent reduction of the nitro groups on nitroaromatic and nitroheterocyclic compounds.

  • BioCyc. gene/protein/disease-specific - nfsB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18355273.001).
  • [ISSN] 0168-6445
  • [Journal-full-title] FEMS microbiology reviews
  • [ISO-abbreviation] FEMS Microbiol. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Nitro Compounds; EC 1.7.- / Nitroreductases
  • [Number-of-references] 256
  •  go-up   go-down


26. Xiao Z, Xu P: Acetoin metabolism in bacteria. Crit Rev Microbiol; 2007 Apr-Jun;33(2):127-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The excretion of acetoin, which can be diagnosed by the Voges Proskauer test and serves as a microbial classification marker, has its vital physiological meanings to these microbes mainly including avoiding acification, participating in the regulation of NAD/NADH ratio, and storaging carbon.

  • Hazardous Substances Data Bank. ACETOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558661.001).
  • [ISSN] 1040-841X
  • [Journal-full-title] Critical reviews in microbiology
  • [ISO-abbreviation] Crit. Rev. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA-Binding Proteins; 0 / Repressor Proteins; 0 / catabolite control proteins, bacteria; BG4D34CO2H / Acetoin
  • [Number-of-references] 159
  •  go-up   go-down


27. Hishida A, Terakura S, Emi N, Yamamoto K, Murata M, Nishio K, Sekido Y, Niwa T, Hamajima N, Naoe T: GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese. Asian Pac J Cancer Prev; 2005 Jul-Sep;6(3):251-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a prevalent case-control study with 51 chronic myelogenous leukemia (CML) cases and 476 controls to investigate the associations between glutathione S-transferase T1 (GSTT1), glutathione S-transferase M1 (GSTM1) deletions, and the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism with risk of chronic myelocytic leukemia in Japanese.
  • Incidence case-control studies with a larger statistical power are now required to confirm our findings.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235982.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


28. Lindner HA, Nadeau G, Matte A, Michel G, Ménard R, Cygler M: Site-directed mutagenesis of the active site region in the quinate/shikimate 5-dehydrogenase YdiB of Escherichia coli. J Biol Chem; 2005 Feb 25;280(8):7162-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent YdiB and AroE crystal structures revealed the presence of a NAD(P)-binding and a catalytic domain.

  • BioCyc. gene/protein/disease-specific - ydiB .
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. L-Lysine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596430.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Escherichia coli Proteins; 058C04BGYI / Quinic Acid; 30KYC7MIAI / Aspartic Acid; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.1.25 / Shikimate dehydrogenase; K3Z4F929H6 / Lysine
  •  go-up   go-down


29. Fukushima T, Wada T, Ohtsu H, Tanaka K: Photoinduced four- and six-electron reduction of mononuclear ruthenium complexes having NAD+ analogous ligands. Dalton Trans; 2010 Dec 28;39(48):11526-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoinduced four- and six-electron reduction of mononuclear ruthenium complexes having NAD+ analogous ligands.
  • The high efficiency photochemical two-, four- and six-electron reductions of [Ru(bpy)(2)(pbn)](2+) ([1](2+)), [2](2+) and [3](2+), respectively, by taking advantage of proton coupled two electron reduction of NAD(+) analogous type ligands such as pbn opens a general pathway for multi-electron reduction of metal complexes via illumination with visible light.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20830398.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Li M, Li Y, Chen J, Wei W, Pan X, Liu J, Liu Q, Leu W, Zhang L, Yang X, Lu J, Wang K: Copper ions inhibit S-adenosylhomocysteine hydrolase by causing dissociation of NAD+ cofactor. Biochemistry; 2007 Oct 16;46(41):11451-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Copper ions inhibit S-adenosylhomocysteine hydrolase by causing dissociation of NAD+ cofactor.
  • Binding of Cu2+ to SAHH resulted in the release of NAD+ cofactors, explaining the loss of the enzymatic activity of SAHH.
  • Further investigation by an ESR probe and computational simulation suggested that Cu2+ could bind at the central channel and interrupt the subunit interactions of SAHH, resulting in a large decrease in affinity to the NAD+ cofactor.
  • [MeSH-major] Adenosylhomocysteinase / antagonists & inhibitors. Adenosylhomocysteinase / chemistry. Copper / pharmacology. NAD / metabolism

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892301.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoenzymes; 0 / Recombinant Proteins; 0U46U6E8UK / NAD; 789U1901C5 / Copper; EC 3.3.1.1 / Adenosylhomocysteinase
  •  go-up   go-down


31. Petrova GV, Donchenko GV: [Cytotoxicity of troglitazone, structural analogue of alpha-tocopherol is mediated by inhibition of NAD(P)H:quinone oxidoreductase]. Ukr Biokhim Zh (1999); 2009 Jul-Aug;81(4):105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytotoxicity of troglitazone, structural analogue of alpha-tocopherol is mediated by inhibition of NAD(P)H:quinone oxidoreductase].
  • It is established, that alpha-tocopherol and pioglitazone in concentration up to 100 microM did not change the rat thymocytes viability while troglitazone and alpha-tocopherol with a short side chain up to 6 atoms of carbon (alpha-tocopherol C6) have the expressed cytotoxic effect.
  • This is the first report demonstrating that troglitazone and alpha-tocopherol C6, unlike a-tocopherol and pioglitazone substantially inhibited the activity of NAD(P)H:quinone oxidoreductase (DT-diaphorase) and this effect is increased with specific DT-diaphorase inhibitor, dicoumarol.
  • Based on these observations, we generalize that cytotoxic action of troglitazone and alpha-tocopherol C6 is connected with the presence in their structure of chroman ring with a lateral chain modified in relation to alpha-tocopherol and is mediated by inhibition of DT-diaphorase, a detoxifying enzyme of xenobiotics.
  • [MeSH-major] Chromans / pharmacology. NAD(P)H Dehydrogenase (Quinone) / antagonists & inhibitors. Thiazolidinediones / pharmacology. Thymus Gland / drug effects. alpha-Tocopherol / pharmacology

  • Hazardous Substances Data Bank. VITAMIN E .
  • Hazardous Substances Data Bank. DICUMAROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387640.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Chromans; 0 / Enzyme Inhibitors; 0 / Thiazolidinediones; 7QID3E7BG7 / Dicumarol; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); H4N855PNZ1 / alpha-Tocopherol; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


32. Wang B, Jin F, Xie Y, Tang Y, Kan R, Zheng C, Yang Z, Wang L: Association analysis of NAD(P)H:quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer's disease. Neurosci Lett; 2006 Dec 6;409(3):179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association analysis of NAD(P)H:quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer's disease.
  • Alterations of the NAD(P)H:quinone oxidoreductase (NQO1) activity are associated with Alzheimer's disease (AD).
  • A polymorphism consisting of a single nucleotide (C-->T) change at position 609 of NQO1 influences the NQO1 activity.
  • [MeSH-major] Alzheimer Disease / enzymology. Alzheimer Disease / epidemiology. Genetic Testing / methods. NAD(P)H Dehydrogenase (Quinone) / genetics. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027152.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


33. Zhou M, Deng L, Wen D, Shang L, Jin L, Dong S: Highly ordered mesoporous carbons-based glucose/O2 biofuel cell. Biosens Bioelectron; 2009 May 15;24(9):2904-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OMCs are used as supports for both stably confining the electrocatalyst (i.e., meldola's blue, MDB) for NADH oxidation and the anodic biocatalyst (i.e., NAD(+)-dependent glucose dehydrogenase, GDH) for glucose oxidation, and for facilitating direct electrochemistry of the cathodic biocatalyst (i.e., laccase, LAC) for O(2) electroreduction.
  • In 0.10 M pH 6.0 PBS containing 20 mM NAD(+) and 60 mM glucose under the air-saturated atmosphere, the open circuit voltage (0.82 V) and the maximum power output (38.7 microW cm(-2) (at 0.54 V)) of the assembled compartment-less OMCs-based BFC are both higher than those of carbon nanotubes (CNTs)-based BFC (0.75 V and 2.1 microW cm(-2) (at 0.46 V)).
  • [MeSH-minor] Catalysis. Electrochemistry. Electrodes. Kinetics. NAD / chemistry. Oxazines / chemistry. Oxidation-Reduction. Porosity

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321330.001).
  • [ISSN] 1873-4235
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nanotubes, Carbon; 0 / Oxazines; 0U46U6E8UK / NAD; 7057-57-0 / Meldola blue; EC 1.1.1.47 / Glucose 1-Dehydrogenase; IY9XDZ35W2 / Glucose; S88TT14065 / Oxygen
  •  go-up   go-down


34. Zou CG, Zhao YS, Gao SY, Li SD, Cao XZ, Zhang M, Zhang KQ: Homocysteine promotes proliferation and activation of microglia. Neurobiol Aging; 2010 Dec;31(12):2069-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Homocysteine promoted the activity of NAD(P)H oxidases, resulting in the generation of reactive oxygen species.
  • Up-regulation of NAD(P)H oxidase activity by homocysteine appears to be due to its ability to induce the phosphorylation of p47phox through the p38 MAPK pathway.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Inc. All rights reserved.
  • (PMID = 19131143.001).
  • [ISSN] 1558-1497
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0LVT1QZ0BA / Homocysteine; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


35. Yang KT, Chang WL, Yang PC, Chien CL, Lai MS, Su MJ, Wu ML: Activation of the transient receptor potential M2 channel and poly(ADP-ribose) polymerase is involved in oxidative stress-induced cardiomyocyte death. Cell Death Differ; 2006 Oct;13(10):1815-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The apoptotic component is caused by the activation of clotrimazole-sensitive, NAD(+)/ADP ribose/poly(ADP-ribose) polymerase (PARP)-dependent transient receptor potential M2 (TRPM2) channels, which induces mitochondrial [Na(+)](m) (and [Ca(2+)](m)) overload, resulting in mitochondrial membrane disruption, cytochrome c release, and caspase 3-dependent chromatin condensation/fragmentation.
  • The necrotic component is caspase 3-independent and is caused by PARP-induced [ATP](i)/NAD(+) depletion, resulting in membrane permeabilization.
  • [MeSH-minor] Animals. Animals, Newborn. Apoptosis / drug effects. Apoptosis / physiology. Calcium / metabolism. Caspase 3. Caspases / metabolism. Female. Hydrogen Peroxide / pharmacology. In Vitro Techniques. Male. Mitochondria, Heart / drug effects. Mitochondria, Heart / metabolism. Models, Cardiovascular. NAD / metabolism. Necrosis. Oxidative Stress / drug effects. Rats. Rats, Wistar. Sodium / metabolism

  • Guide to Pharmacology. gene/protein/disease-specific - TRPM2 - data and references .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294211.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TRPM Cation Channels; 0U46U6E8UK / NAD; 9NEZ333N27 / Sodium; BBX060AN9V / Hydrogen Peroxide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; SY7Q814VUP / Calcium
  •  go-up   go-down


36. Agledal L, Niere M, Ziegler M: The phosphate makes a difference: cellular functions of NADP. Redox Rep; 2010;15(1):2-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The generation of NADP by NAD kinases is a key determinant of the cellular NADP concentration.
  • [MeSH-minor] Animals. Calcium Signaling / physiology. Cytochrome P-450 Enzyme System / metabolism. Humans. NAD+ Nucleosidase / metabolism. NADPH Oxidase / metabolism. Oxidative Stress. Phosphotransferases (Alcohol Group Acceptor) / metabolism. Plants / metabolism. Reactive Oxygen Species / metabolism. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196923.001).
  • [ISSN] 1743-2928
  • [Journal-full-title] Redox report : communications in free radical research
  • [ISO-abbreviation] Redox Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 53-59-8 / NADP; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.23 / NAD kinase; EC 3.2.2.5 / NAD+ Nucleosidase
  • [Number-of-references] 68
  •  go-up   go-down


37. Gomez C, Bandez MJ, Navarro A: Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front Biosci; 2007;12:1079-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toxicants that inhibit selectively NADH-dehydrogenase activity, as rotenone or pyridaben, also show a selective inhibition of O2 uptake and respiratory control in rat brain mitochondria in the presence of NAD-dependent substrates.
  • In rat brain mitochondria, rotenone and pyridaben markedly decreased mtNOS functional activity with NAD-dependent substrates but not when the substrate was succinate.

  • MedlinePlus Health Information. consumer health - Pesticides.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. Paraquat .
  • Hazardous Substances Data Bank. ROTENONE .
  • Hazardous Substances Data Bank. PYRIDABEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127363.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Free Radicals; 0 / Pesticides; 0 / Pyridazines; 03L9OT429T / Rotenone; 2E4JBA5272 / pyridaben; 31C4KY9ESH / Nitric Oxide; PLG39H7695 / Paraquat
  • [Number-of-references] 135
  •  go-up   go-down


38. Keppetipola N, Shuman S: Characterization of a thermophilic ATP-dependent DNA ligase from the euryarchaeon Pyrococcus horikoshii. J Bacteriol; 2005 Oct;187(20):6902-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a thermophilic ATP-dependent DNA ligase from the euryarchaeon Pyrococcus horikoshii.
  • Archaea encode a DNA ligase composed of a C-terminal catalytic domain typical of ATP-dependent ligases plus an N-terminal domain similar to that found in eukaryotic cellular and poxvirus DNA ligases.
  • However, recent reports of dual-specificity ATP/NAD+ ligases in two Thermococcus species and Pyrococcus abyssi and an ATP/ADP ligase in Aeropyrum pernix raise the prospect that certain archaeal enzymes might exemplify an undifferentiated ancestral stage in the evolution of ligase substrate specificity.
  • Here we analyze the biochemical properties of Pyrococcus horikoshii DNA ligase. P. horikoshii ligase catalyzes auto-adenylylation and nick sealing in the presence of a divalent cation and ATP; it is unable to utilize NAD+ or ADP to promote ligation in lieu of ATP. P. horikoshii ligase is thermophilic in vitro, with optimal adenylyltransferase activity at 90 degrees C and nick-joining activity at 70 to 90 degrees C. P. horikoshii ligase resembles the ligases of Methanobacterium thermautotrophicum and Sulfolobus shibatae in its strict specificity for ATP.

  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Jun 1;28(11):2221-8 [10871342.001]
  • [Cites] Curr Opin Struct Biol. 2004 Dec;14(6):757-64 [15582400.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(6):1241-8 [11442824.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36100-9 [11459847.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1183-93 [11106756.001]
  • [Cites] Extremophiles. 2002 Feb;6(1):45-50 [11878561.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):9695-700 [11781321.001]
  • [Cites] Extremophiles. 2002 Dec;6(6):469-77 [12486455.001]
  • [Cites] Genome Biol. 2003;4(8):115 [12914651.001]
  • [Cites] FEBS Lett. 2003 Aug 28;550(1-3):69-73 [12935888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12984-8 [14566062.001]
  • [Cites] FEMS Microbiol Lett. 2004 Jul 15;236(2):267-73 [15251207.001]
  • [Cites] Structure. 2004 Aug;12(8):1449-59 [15296738.001]
  • [Cites] J Biol Chem. 1968 Sep 10;243(17):4556-63 [4879168.001]
  • [Cites] Science. 1974 Nov 29;186(4166):790-7 [4377758.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5389-96 [1437556.001]
  • [Cites] Cell. 1996 May 17;85(4):607-15 [8653795.001]
  • [Cites] Nucleic Acids Res. 1997 Feb 15;25(4):727-34 [9016621.001]
  • [Cites] Cell. 1997 May 16;89(4):545-53 [9160746.001]
  • [Cites] Cell. 1997 Jun 27;89(7):995-8 [9215620.001]
  • [Cites] DNA Res. 1998 Apr 30;5(2):55-76 [9679194.001]
  • [Cites] FEBS Lett. 1998 Aug 21;433(3):283-6 [9744812.001]
  • [Cites] Nucleic Acids Res. 1998 Oct 15;26(20):4618-25 [9753729.001]
  • [Cites] Eur J Biochem. 1999 May;261(3):802-11 [10215898.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 1;27(17):3389-401 [10446225.001]
  • [Cites] Nature. 2004 Nov 25;432(7016):473-8 [15565146.001]
  • [Cites] J Bacteriol. 2000 Nov;182(22):6424-33 [11053387.001]
  • (PMID = 16199559.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM063611; United States / NIGMS NIH HHS / GM / GM63611
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Archaeal Proteins; 0 / DNA, Archaeal; 415SHH325A / Adenosine Monophosphate; 61D2G4IYVH / Adenosine Diphosphate; 8L70Q75FXE / Adenosine Triphosphate; EC 2.7.7.- / Nucleotidyltransferases; EC 6.5.1.- / DNA Ligases
  • [Other-IDs] NLM/ PMC1251619
  •  go-up   go-down


39. Trechot P, Barbaud A, Petitpain N, Claeys A, Schmutz JL: Nicorandil and ulcerations: a NAD/NADP and nicotinic acid-dependent side-effect? Br J Dermatol; 2008 May;158(5):1150-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nicorandil and ulcerations: a NAD/NADP and nicotinic acid-dependent side-effect?
  • [MeSH-minor] Humans. NAD. NADP

  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341661.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vasodilator Agents; 0U46U6E8UK / NAD; 25X51I8RD4 / Niacinamide; 260456HAM0 / Nicorandil; 2679MF687A / Niacin; 53-59-8 / NADP
  •  go-up   go-down


40. Paz-Y-Miño C G, Espinosa A: Integrating horizontal gene transfer and common descent to depict evolution and contrast it with "common design". J Eukaryot Microbiol; 2010 Jan-Feb;57(1):11-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Natural selection has driven the evolution of EhADH2 active sites, which require specific amino acids (cysteine 252 in the ALDH domain; histidine 754 in the ADH domain), iron- and NAD(+) as cofactors, and the substrates acetyl-CoA for ALDH and acetaldehyde for ADH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021546.001).
  • [ISSN] 1550-7408
  • [Journal-full-title] The Journal of eukaryotic microbiology
  • [ISO-abbreviation] J. Eukaryot. Microbiol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / P20 GM103430; United States / NCRR NIH HHS / RR / P20 RR016457; United States / NCRR NIH HHS / RR / P20RR16457-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  • [Other-IDs] NLM/ NIHMS769876; NLM/ PMC4813655
  •  go-up   go-down


41. Kaur S, Shivange AV, Roy N: Structural analysis of trypanosomal sirtuin: an insight for selective drug design. Mol Divers; 2010 Feb;14(1):169-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sirtuin family of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases are remarkably conserved throughout evolution from archaebacteria to eukaryotes and plays an important role in trypanosomatidae biology and virulence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2003 Nov 3;22(21):5851-62 [14592982.001]
  • [Cites] Br Med Bull. 1985 Apr;41(2):105-14 [3928017.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):235-42 [10592235.001]
  • [Cites] Int J Cardiol. 2007 Feb 14;115(3):279-83 [16769134.001]
  • [Cites] Chem Res Toxicol. 1999 May;12 (5):422-8 [10328752.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1256-64 [17490721.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):463-72 [17289592.001]
  • [Cites] Trends Microbiol. 1999 Feb;7(2):82-8 [10081086.001]
  • [Cites] Curr Top Med Chem. 2002 May;2(5):471-82 [11966468.001]
  • [Cites] BMC Genomics. 2005 Sep 15;6:127 [16164760.001]
  • [Cites] Gene. 1996 Feb 22;169(1):115-8 [8635734.001]
  • [Cites] Ann Med. 2007;39(5):335-45 [17701476.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):83-5 [1538787.001]
  • [Cites] Biophys J. 2002 Jun;82(6):2906-15 [12023213.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Feb;49(2):808-12 [15673775.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 5;273(2):793-8 [10873683.001]
  • [Cites] Acta Trop. 2005 May;94(2):107-15 [15860278.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Chem Biol Drug Des. 2008 May;71(5):501-6 [18373547.001]
  • [Cites] Lancet Infect Dis. 2002 Aug;2(8):494-501 [12150849.001]
  • [Cites] Structure. 2003 Nov;11(11):1403-11 [14604530.001]
  • [Cites] Mol Cell. 2005 Mar 18;17(6):855-68 [15780941.001]
  • [Cites] Gene. 2002 Aug 21;296(1-2):139-50 [12383511.001]
  • [Cites] Clin Immunol. 1999 Jul;92(1):56-66 [10413653.001]
  • [Cites] Nat Struct Biol. 2001 Jul;8(7):621-5 [11427894.001]
  • [Cites] BMJ. 2003 Feb 15;326(7385):377-82 [12586674.001]
  • [Cites] Bioorg Med Chem. 1998 Oct;6(10 ):1927-33 [9839022.001]
  • (PMID = 19404761.001).
  • [ISSN] 1573-501X
  • [Journal-full-title] Molecular diversity
  • [ISO-abbreviation] Mol. Divers.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuin 2
  •  go-up   go-down


42. Niesner RA, Andresen V, Gunzer M: Intravital two-photon microscopy: focus on speed and time resolved imaging modalities. Immunol Rev; 2008 Feb;221:7-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we describe currently available two-photon microscopy techniques with a focus on novel approaches that allow very high image acquisition rates compared with state-of-the-art systems.
  • We focus on the analysis of endogenous fluorophores such as NAD(P)H as a way to analyze the redox status in cells with subcellular resolution.
  • [MeSH-minor] Equipment Design. Fluorescence. Image Processing, Computer-Assisted. NAD. NADP

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275472.001).
  • [ISSN] 1600-065X
  • [Journal-full-title] Immunological reviews
  • [ISO-abbreviation] Immunol. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0U46U6E8UK / NAD; 53-59-8 / NADP
  •  go-up   go-down


43. Bosch D, Johansson M, Ferndahl C, Franzén CJ, Larsson C, Gustafsson L: Characterization of glucose transport mutants of Saccharomyces cerevisiae during a nutritional upshift reveals a correlation between metabolite levels and glycolytic flux. FEMS Yeast Res; 2008 Feb;8(1):10-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reducing the rate of sugar consumption caused an accumulation of hexose phosphates upstream of the phosphofructokinase (PFK) and a reduction of fructose-1,6-bisphosphate levels.
  • Moreover, the model indicated a modified sensitivity of the pyruvate dehydrogenase and the trichloroacetic acid cycle enzymes towards the NAD/NADH in the TM6* strain.
  • The activation of the SNF1 sugar signalling pathway, previously observed in the TM6* strain, does not correlate with a reduction of the ATP : AMP ratio as reported in mammals.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042231.001).
  • [ISSN] 1567-1356
  • [Journal-full-title] FEMS yeast research
  • [ISO-abbreviation] FEMS Yeast Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hexosephosphates; EC 2.7.1.11 / Phosphofructokinase-1; IY9XDZ35W2 / Glucose
  •  go-up   go-down


44. Peterson JR, Sharma RV, Davisson RL: Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep; 2006 Jun;8(3):232-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As in the peripheral vasculature, NAD(P)H oxidase appears to be a major enzymatic source of brain ROS, and various homologues of the catalytic subunit of this enzyme appear to be differentially localized to cardiovascular-regulating nuclei in the brain.
  • Recent studies have begun to elucidate the downstream effects of ROS in neurons, and it is now clear that ROS may interact with a number of well-described intracellular signaling pathways involved in neuronal activation.
  • In this review, we discuss recent evidence in support of a role for brain ROS in the pathogenesis of hypertension and summarize current studies aimed at uncovering the complex mechanisms by which brain ROS regulate blood pressure in both health and cardiovascular disease.

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2005 Jan;45(1):9-14 [15583075.001]
  • [Cites] Neuroendocrinology. 1981 Apr;32(4):248-56 [7012657.001]
  • [Cites] Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1315-26 [16115037.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H20-9 [15749748.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):247-54 [11160145.001]
  • [Cites] Circulation. 2004 May 18;109(19):2357-62 [15117836.001]
  • [Cites] Circ Res. 2002 Nov 29;91(11):1038-45 [12456490.001]
  • [Cites] Hypertens Res. 2004 Jul;27(7):485-92 [15302985.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):9944-52 [15525779.001]
  • [Cites] Circ Res. 2004 Feb 20;94(3):402-9 [14684626.001]
  • [Cites] Circ Res. 2005 Feb 4;96(2):252-60 [15591232.001]
  • [Cites] Circ Res. 2004 Sep 3;95(5):532-9 [15271858.001]
  • [Cites] Peptides. 2001 Nov;22(11):1803-7 [11754966.001]
  • [Cites] FASEB J. 2005 Apr;19(6):626-8 [15659536.001]
  • [Cites] Regul Pept. 2005 May 15;128(1):1-5 [15721481.001]
  • [Cites] Nat Med. 1998 Feb;4(2):245-7 [9461201.001]
  • [Cites] Circ Res. 2005 Oct 14;97(8):772-80 [16151022.001]
  • [Cites] Circ Res. 2000 Jun 23;86(12):1266-72 [10864918.001]
  • [Cites] Circ Res. 2005 Apr 1;96(6):659-66 [15746442.001]
  • [Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1583-96 [16987013.001]
  • [Cites] Circ Res. 1977 May;40(5 Suppl 1):I110-7 [858173.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;940:xiii-xxii [11458711.001]
  • [Cites] Heart. 2004 May;90(5):491-3 [15084538.001]
  • [Cites] Curr Hypertens Rep. 2005 Apr;7(2):135-40 [15748539.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R259-76 [12529279.001]
  • [Cites] J Neurosci. 2004 Jun 16;24(24):5516-24 [15201324.001]
  • [Cites] Biochemistry (Mosc). 2002 Mar;67(3):281-92 [11970728.001]
  • [Cites] Front Biosci. 2004 Jan 01;9:8-23 [14766339.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):483-90 [12010196.001]
  • [Cites] Cell. 2004 Aug 20;118(4):453-64 [15315758.001]
  • [Cites] Trends Neurosci. 2005 Jan;28(1):37-43 [15626495.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:67-101 [10331077.001]
  • [Cites] J Neurophysiol. 2006 Feb;95(2):1042-8 [16267117.001]
  • [Cites] J Cardiovasc Pharmacol. 2000;35(7 Suppl 4):S1-7 [11346214.001]
  • [Cites] Hypertension. 2004 Sep;44(3):248-52 [15262903.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H111-5 [15308481.001]
  • [Cites] Mol Cell Biochem. 2000 Sep;212(1-2):155-69 [11108147.001]
  • [Cites] Free Radic Biol Med. 2005 Dec 15;39(12):1601-10 [16298685.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):440-6 [15854155.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2626-33 [15284074.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2271-9 [15637113.001]
  • [Cites] Hypertension. 2002 Sep;40(3):335-41 [12215476.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1148-53 [15802625.001]
  • [Cites] Hypertension. 2005 Sep;46(3):533-9 [16116043.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):462-6 [15854159.001]
  • [Cites] Circ Res. 2004 Jul 23;95(2):210-6 [15192025.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5552-60 [16123155.001]
  • [Cites] Hypertension. 2005 Apr;45(4):717-23 [15699459.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):181-9 [15039755.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Sep;285(3):R632-40 [12738610.001]
  • [Cites] Circ Res. 1994 Jun;74(6):1141-8 [8187280.001]
  • [Cites] Free Radic Biol Med. 2005 Feb 15;38(4):450-62 [15649647.001]
  • [Cites] J Neurosci. 2004 Dec 1;24(48):10878-87 [15574738.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Oct;315(1):51-7 [15951402.001]
  • [Cites] Circ Res. 2001 Aug 31;89(5):408-14 [11532901.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 17;310(2):470-7 [14521934.001]
  • [Cites] Circ Res. 2005 Nov 11;97(10 ):975-82 [16224066.001]
  • [Cites] J Clin Invest. 2000 Jul;106(1):103-6 [10880053.001]
  • [Cites] Heart Fail Rev. 2000 Mar;5(1):27-43 [16228914.001]
  • [Cites] J Mol Med (Berl). 1999 Mar;77(3):339-57 [10090597.001]
  • [Cites] Hypertension. 2005 Jun;45(6):1165-72 [15867131.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1980;87:117-67 [6252591.001]
  • [Cites] Prog Biophys Mol Biol. 2004 Feb-Apr;84(2-3):125-49 [14769433.001]
  • [Cites] Exp Physiol. 2005 Jul;90(4):449-55 [15890798.001]
  • (PMID = 17147922.001).
  • [ISSN] 1522-6417
  • [Journal-full-title] Current hypertension reports
  • [ISO-abbreviation] Curr. Hypertens. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Transcription Factors; 11128-99-7 / Angiotensin II; 31C4KY9ESH / Nitric Oxide; EC 1.6.3.1 / NADPH Oxidase
  • [Number-of-references] 65
  •  go-up   go-down


45. Galati G, Lin A, Sultan AM, O'Brien PJ: Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med; 2006 Feb 15;40(4):570-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, GSH conjugation, methylation, metabolism by NAD(P)H:quinone oxidoreductase 1, and formation of an iron complex were important in detoxifying the gallic acid.
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Antioxidants / toxicity. Glutathione / metabolism. Iron / metabolism. Male. Mass Spectrometry. Methylation. Mice. NAD(P)H Dehydrogenase (Quinone) / genetics. NAD(P)H Dehydrogenase (Quinone) / metabolism. Rats. Rats, Sprague-Dawley

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. GALLIC ACID .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Free Radic Biol Med. 2007 Aug 1;43(3):474 [17602963.001]
  • (PMID = 16458187.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Hydroxybenzoates; 0 / Tea; 29656-58-4 / phenolic acid; 632XD903SP / Gallic Acid; 8R1V1STN48 / Catechin; 92587OVD8Z / epicatechin gallate; BQM438CTEL / epigallocatechin gallate; E1UOL152H7 / Iron; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, rat; EC 2.6.1.2 / Alanine Transaminase; GAN16C9B8O / Glutathione
  •  go-up   go-down


46. Pacher P, Szabó C: Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal; 2005 Nov-Dec;7(11-12):1568-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARP activation, on the one hand, depletes its substrate, NAD+, slowing the rate of glycolysis, electron transport, and ATP formation.

  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Antioxid. Redox Signal. 7, 1568-1580.
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L240-9 [12626333.001]
  • [Cites] Mutat Res. 2003 Jun 19;527(1-2):49-55 [12787913.001]
  • [Cites] Diabetes Care. 2003 Aug;26(8):2433-41 [12882875.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1514-6 [12824290.001]
  • [Cites] Diabetes. 2003 Sep;52(9):2363-71 [12941777.001]
  • [Cites] Trends Pharmacol Sci. 2003 Sep;24(9):471-8 [12967772.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):986-8 [14523035.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1049-57 [14523042.001]
  • [Cites] Diabetes. 2003 Nov;52(11):2795-804 [14578299.001]
  • [Cites] Clin Exp Nephrol. 2003 Mar;7(1):1-8 [14586737.001]
  • [Cites] Curr Diab Rep. 2003 Dec;3(6):439-45 [14611738.001]
  • [Cites] Diabetes. 2004 Mar;53(3):711-20 [14988256.001]
  • [Cites] Int J Mol Med. 2004 Jul;14(1):55-64 [15202016.001]
  • [Cites] Diabetologia. 2004 Apr;47(4):710-7 [15298348.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1453-9 [15304054.001]
  • [Cites] Mol Med. 2004 Jan-Jun;10(1-6):28-35 [15502880.001]
  • [Cites] Diabetes. 2004 Nov;53(11):2960-7 [15504977.001]
  • [Cites] Biochem Biophys Res Commun. 1980 Dec 31;97(4):1311-6 [6260088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jun;79(11):3423-7 [6808510.001]
  • [Cites] Environ Mutagen. 1983;5(4):515-25 [6307677.001]
  • [Cites] Diabetes Res. 1985 Nov;2(6):307-12 [2934204.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):653-6 [3543058.001]
  • [Cites] Pediatr Res. 1989 Jan;25(1):97-101 [2521933.001]
  • [Cites] J Cell Physiol. 1989 Jul;140(1):177-85 [2500451.001]
  • [Cites] FASEB J. 2000 Feb;14(2):271-8 [10657983.001]
  • [Cites] Nature. 2000 Apr 13;404(6779):787-90 [10783895.001]
  • [Cites] Circ Res. 2000 May 12;86(9):E85-90 [10807876.001]
  • [Cites] Br J Pharmacol. 2000 Jul;130(5):963-74 [10882379.001]
  • [Cites] Mutat Res. 2001 Feb 20;490(2):123-9 [11342238.001]
  • [Cites] Mutat Res. 2001 Jun 2;477(1-2):97-110 [11376691.001]
  • [Cites] Exp Cell Res. 2001 Aug 1;268(1):7-13 [11461113.001]
  • [Cites] J Mol Med (Berl). 2001 Aug;79(8):437-48 [11511974.001]
  • [Cites] Circ Res. 2001 Oct 12;89(8):684-91 [11597991.001]
  • [Cites] Diabetes. 2001 Dec;50(12):2837-41 [11723068.001]
  • [Cites] Nature. 2001 Dec 13;414(6865):813-20 [11742414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):245-50 [11756665.001]
  • [Cites] Circ Res. 2002 Jan 11;90(1):100-6 [11786525.001]
  • [Cites] Circ Res. 2002 Jan 11;90(1):107-11 [11786526.001]
  • [Cites] Diabetes. 2002 Feb;51(2):514-21 [11812763.001]
  • [Cites] Heart. 2002 Mar;87(3):264-9 [11847169.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Mar;300(3):862-7 [11861791.001]
  • [Cites] Br J Pharmacol. 2002 Mar;135(6):1347-50 [11906946.001]
  • [Cites] Circulation. 2002 Apr 9;105(14):1656-62 [11940543.001]
  • [Cites] Shock. 2002 Apr;17(4):286-92 [11954828.001]
  • [Cites] Curr Drug Metab. 2002 Apr;3(2):159-73 [12003348.001]
  • [Cites] Crit Care Med. 2002 May;30(5):1071-82 [12006805.001]
  • [Cites] Br J Pharmacol. 2002 May;136(2):255-63 [12010774.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23234-9 [10930429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10203-8 [10954738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11274-9 [11016956.001]
  • [Cites] Circ Res. 2000 Nov 10;87(10):840-4 [11073878.001]
  • [Cites] Trends Pharmacol Sci. 2005 Jun;26(6):302-10 [15925705.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):221-9 [16026319.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jul;3(3):285-91 [16026324.001]
  • [Cites] Circ Res. 1998 Sep 21;83(6):644-51 [9742060.001]
  • [Cites] Free Radic Biol Med. 2000 Nov 15;29(10):995-1004 [11084288.001]
  • [Cites] Semin Thromb Hemost. 2000;26(5):529-37 [11129409.001]
  • [Cites] Nat Med. 2001 Jan;7(1):108-13 [11135624.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):36-52 [11159815.001]
  • [Cites] Int J Mol Med. 2002 Jun;9(6):659-64 [12011985.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 2):1S13-7 [12037502.001]
  • [Cites] Circ Res. 2002 Jun 28;90(12):1274-81 [12089065.001]
  • [Cites] J Neurochem. 2002 Jul;82(1):19-29 [12091461.001]
  • [Cites] Circulation. 2002 Aug 20;106(8):927-32 [12186795.001]
  • [Cites] Pharmacol Rev. 2002 Sep;54(3):375-429 [12223530.001]
  • [Cites] J Am Coll Cardiol. 2002 Sep 4;40(5):1006-16 [12225730.001]
  • [Cites] Circulation. 2002 Nov 19;106(21):2680-6 [12438293.001]
  • [Cites] Biochem Pharmacol. 2002 Dec 15;64(12):1785-91 [12445868.001]
  • [Cites] Mol Med. 2002 Oct;8(10):571-80 [12477967.001]
  • [Cites] Curr Med Chem. 2003 Feb;10(4):321-40 [12570705.001]
  • [Cites] Curr Diab Rep. 2002 Dec;2(6):501-9 [12643157.001]
  • [Cites] Biochim Biophys Acta. 1991 May 17;1092(3):319-25 [1904775.001]
  • [Cites] Arch Biochem Biophys. 1991 May 1;286(2):353-63 [1654786.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):356-8 [1549180.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Jan;36(1):91-5 [1532770.001]
  • [Cites] FASEB J. 1992 Aug;6(11):2905-14 [1644256.001]
  • [Cites] Mol Cell Biochem. 1993 May 26;122(2):171-93 [8232248.001]
  • [Cites] Biochem Pharmacol. 1994 Nov 1;48(9):1757-65 [7980645.001]
  • [Cites] Mol Cell Biochem. 1994 Sep;138(1-2):15-24 [7898458.001]
  • [Cites] Microcirculation. 1996 Mar;3(1):39-47 [8846270.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1753-8 [8700830.001]
  • [Cites] Diabetes Care. 1996 Mar;19(3):257-67 [8742574.001]
  • [Cites] Atherosclerosis. 1996 May;122(2):163-72 [8769680.001]
  • [Cites] Rheumatol Int. 1995;15(4):171-2 [8835300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):679-83 [9012844.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7303-7 [9207086.001]
  • [Cites] J Clin Invest. 1997 Aug 1;100(3):723-35 [9239421.001]
  • [Cites] Br J Pharmacol. 1997 Jul;121(6):1065-74 [9249240.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1089-95 [9334719.001]
  • [Cites] Int J Radiat Biol. 1998 Mar;73(3):325-30 [9525261.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3867-72 [9520459.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Apr 7;245(1):1-10 [9535773.001]
  • [Cites] Mutat Res. 1998 Feb 26;398(1-2):151-61 [9626975.001]
  • [Cites] Circ Res. 1998 Jul 13;83(1):85-94 [9670921.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9220-5 [9689061.001]
  • [Cites] Trends Pharmacol Sci. 1998 Jul;19(7):287-98 [9703762.001]
  • [Cites] Life Sci. 1998;63(11):923-33 [9747893.001]
  • [Cites] J Cardiovasc Pharmacol. 1998;32 Suppl 3:S54-61 [9883749.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3059-64 [10077636.001]
  • [Cites] Nat Med. 1999 Mar;5(3):314-9 [10086388.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4446-54 [10449410.001]
  • [Cites] Diabetes. 1999 Sep;48(9):1856-62 [10480619.001]
  • [Cites] Diabetes Care. 1999 Oct;22(10):1626-31 [10526726.001]
  • [Cites] Diabetes. 2005 Jan;54(1):234-42 [15616034.001]
  • [Cites] Curr Med Chem. 2005;12(3):267-75 [15723618.001]
  • [Cites] FASEB J. 2005 Mar;19(3):401-3 [15611153.001]
  • [Cites] Am J Manag Care. 2003 Mar;9(3 Suppl):S63-80; quiz S81-4 [12653455.001]
  • [Cites] Biochem Pharmacol. 2003 Apr 1;65(7):1189-97 [12663054.001]
  • [Cites] Expert Opin Pharmacother. 2003 Apr;4(4):525-32 [12667115.001]
  • [Cites] Diabetologia. 2003 Mar;46(3):401-8 [12687339.001]
  • [Cites] Diabetes Care. 2003 May;26(5):1589-96 [12716823.001]
  • (PMID = 16356120.001).
  • [ISSN] 1523-0864
  • [Journal-full-title] Antioxidants & redox signaling
  • [ISO-abbreviation] Antioxid. Redox Signal.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AA000375-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 120
  • [Other-IDs] NLM/ NIHMS38133; NLM/ PMC2228261
  •  go-up   go-down


47. Shimizu M, Yuda N, Nakamura T, Tanaka H, Wariishi H: Metabolic regulation at the tricarboxylic acid and glyoxylate cycles of the lignin-degrading basidiomycete Phanerochaete chrysosporium against exogenous addition of vanillin. Proteomics; 2005 Oct;5(15):3919-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracellular proteins were resolved by 2-DE and target protein spots were identified using MALDI-MS after in-gel tryptic digestions.
  • The exogenous addition of other aromatic compounds also caused an increase in its activity, which in turn triggered NAD(P)H production via the action of dehydrogenases in the tricarboxylic acid cycle, heme biosynthesis via the action of aminolevulinic acid synthase on succinyl-CoA, and energy production via activation of the mitochondrial electron transfer system.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VANILLIN .
  • Hazardous Substances Data Bank. GLYOXYLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217726.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzaldehydes; 0 / Glyoxylates; 0 / Proteins; 9005-53-2 / Lignin; CHI530446X / vanillin; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.1.90 / aryl-alcohol dehydrogenase; EC 1.11.1.- / Peroxidases; EC 1.2.1.3 / Aldehyde Dehydrogenase; EC 4.1.3.1 / Isocitrate Lyase; JQ39C92HH6 / glyoxylic acid
  •  go-up   go-down


48. Wojtyczka RD, Kepa M, Brela R, Pacha J, Wydmuch Z, Idzik D: [Legal aspects of the supervision of nosocomial infection]. Wiad Lek; 2007;60(5-6):298-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Aspekty prawne nadzoru nad zakazeniami szpitalnymi.

  • MedlinePlus Health Information. consumer health - Infection Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966899.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


49. Newsome JJ, Colucci MA, Hassani M, Beall HD, Moody CJ: Benzimidazole- and benzothiazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1. Org Biomol Chem; 2007 Nov 21;5(22):3665-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benzimidazole- and benzothiazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1.
  • The ability of these heterocyclic quinones to act as substrates for recombinant human NAD(P)H:quinone oxidoreductase (NQO1), a two-electron reductase upregulated in tumour cells, was determined.
  • [MeSH-major] Benzimidazoles / metabolism. Benzothiazoles / metabolism. NAD(P)H Dehydrogenase (Quinone) / metabolism. Quinones / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BENZIMIDAZOLE .
  • Hazardous Substances Data Bank. BENZOTHIAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971996.001).
  • [ISSN] 1477-0520
  • [Journal-full-title] Organic & biomolecular chemistry
  • [ISO-abbreviation] Org. Biomol. Chem.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 17670
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzimidazoles; 0 / Benzothiazoles; 0 / Quinones; 0 / Recombinant Proteins; E24GX49LD8 / benzimidazole; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; G5BW2593EP / benzothiazole
  •  go-up   go-down


50. Tsukatani T, Matsumoto K: Sequential fluorometric quantification of malic acid enantiomers by a single line flow-injection system using immobilized-enzyme reactors. Talanta; 2005 Jan 30;65(2):396-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sample and coenzyme (NAD(+) or NADP(+)) were injected into the flow line by an open sandwich method. d-Malate was selectively oxidized by d-MDH when NAD(+) was injected with a sample.
  • When NADP(+) was injected with a sample, l-malate was oxidized only by l-MDH.
  • Linear relationships between the responses and concentrations of d-malate and l-malate were observed in the ranges of 1 x 10(-6)-1 x 10(-4)M and 1 x 10(-6)-2 x 10(-4)M, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18969812.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, Sutton D, Gao J, Boothman DA: Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res; 2005 Apr 15;11(8):3055-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
  • beta-Lapachone, an o-naphthoquinone, induces a novel caspase- and p53-independent apoptotic pathway dependent on NAD(P)H:quinone oxidoreductase 1 (NQO1).
  • Interestingly, coadministration of N-acetyl-l-cysteine, prevented derivative-induced cytotoxicity but did not affect beta-lapachone lethality.
  • [MeSH-major] NAD(P)H Dehydrogenase (Quinone) / metabolism. Naphthoquinones / pharmacology. Prodrugs / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837761.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA142543; United States / NCI NIH HHS / CA / R01 CA102792; United States / NCI NIH HHS / CA / 5T32 CA59366; United States / NCI NIH HHS / CA / R01 CA-92250
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Naphthoquinones; 0 / Prodrugs; 4707-32-8 / beta-lapachone; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


52. Wasco MJ, Pu RT, Yu L, Su L, Ma L: Expression of gamma-H2AX in melanocytic lesions. Hum Pathol; 2008 Nov;39(11):1614-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have demonstrated the expression of gamma-H2AX in melanoma and dysplastic nevus, but its diagnostic and prognostic utility in a full range of melanocytic lesions has not been fully studied.
  • We found that gamma-H2AX was observed at higher levels (percentage and intensity of staining) in melanoma in situ (12/13), primary cutaneous melanoma (32/33; with the exception of desmoplastic melanoma), and metastatic melanoma (58/62), which was statistically different from that in benign nevus (7/9), dysplastic nevus (6/10), and Spitz nevus (5/9) considered together (P < .0001).
  • The overexpression of gamma-H2AX in melanoma as opposed to nevus indicates its possible role in melanomagenesis.
  • Based on the overlap in subsets of nevi and melanomas, the potential clinical utility of this antibody remains uncertain until further studies have been carried out in a larger cohort of melanocytic lesions, including borderline cases.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Histones / biosynthesis. Melanoma / metabolism. Nevus / metabolism
  • [MeSH-minor] Dysplastic Nevus Syndrome / metabolism. Female. Gene Expression. Humans. Male. Nevus, Epithelioid and Spindle Cell / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656236.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / H2AFX protein, human; 0 / Histones
  •  go-up   go-down


53. Liu YJ, Norberg FE, Szilágyi A, De Paepe R, Akerlund HE, Rasmusson AG: The mitochondrial external NADPH dehydrogenase modulates the leaf NADPH/NADP+ ratio in transgenic Nicotiana sylvestris. Plant Cell Physiol; 2008 Feb;49(2):251-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plant mitochondria contain alternative external NAD(P)H dehydrogenases, which oxidize cytosolic NADH or NADPH and reduce ubiquinone without inherent linkage to proton pumping and ATP production.
  • However, the AOX induction was substantially weaker than in the complex I-deficient CMSII mutant, previously shown to contain elevated amounts of NAD(P)H dehydrogenases and AOX.
  • The lines overexpressing St-ndb1 had consistently lowered leaf NADPH/NADP+ ratios in the light and variably decreased levels in darkness, but unchanged NADH/NAD+ ratios.
  • CMSII instead had similar NADPH/NADP+ and lower NADH/NAD+ ratios than the wild type.
  • These results demonstrate that St-NDB1 is able to modulate the cellular balance of NADPH and NADP+ at least in the day and that reduction of NADP(H) and NAD(H) is independently controlled.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182402.001).
  • [ISSN] 1471-9053
  • [Journal-full-title] Plant & cell physiology
  • [ISO-abbreviation] Plant Cell Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Plant Proteins; 0 / Reactive Oxygen Species; 53-59-8 / NADP; EC 1.6.99.1 / NADPH Dehydrogenase
  •  go-up   go-down


54. Yang M, Kahn AM: Insulin-inhibited and stimulated cultured vascular smooth muscle cell migration are related to divergent effects on protein phosphatase-2A and autonomous calcium/calmodulin-dependent protein kinase II. Atherosclerosis; 2008 Jan;196(1):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the presence of angiotensin II (Ang II), insulin stimulates NAD(P)H oxidase activity leading to increased VSMC migration.
  • We wished to see whether insulin-stimulated cGMP stimulates protein phosphatase-2A (PP-2A) thereby inhibiting autonomous CaM kinase II and migration, and whether insulin, in the presence of Ang II, inhibits PP-2A and stimulates autonomous CaM kinase II in a NAD(P)H oxidase-dependent manner.
  • It is concluded that insulin in the presence of NO stimulates cGMP which stimulates PP-2A activity causing inhibition of autonomous CaM kinase II activity and thus VSMC migration, and that insulin in the presence of Ang II inhibits PP-2A and stimulates autonomous CaM kinase II activities by a NAD(P)H oxidase-dependent mechanism which are associated with insulin-stimulated NAD(P)H oxidase-dependent migration.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553505.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Insulin; 11128-99-7 / Angiotensin II; 31C4KY9ESH / Nitric Oxide; 85-32-5 / Guanosine Monophosphate; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 3.1.3.16 / Protein Phosphatase 2
  •  go-up   go-down


55. Panieri E, Toietta G, Mele M, Labate V, Ranieri SC, Fusco S, Tesori V, Antonini A, Maulucci G, De Spirito M, Galeotti T, Pani G: Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage. Aging (Albany NY); 2010 Aug;2(8):487-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, stimulation of the AMP-activated Protein Kinase concomitantly inhibited mTOR signaling and cell death, while neither event was affected by overexpression of the NAD+ dependent deacetylase Sirt-1, another cellular sensor of nutrient scarcity.

  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6290-8 [14559816.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):1149-54 [12820363.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2011-5 [14976264.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):585-95 [15146184.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):213-23 [15249583.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):200-5 [15306821.001]
  • [Cites] Curr Biol. 2004 Sep 21;14(18):1650-6 [15380067.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2026-30 [8134344.001]
  • [Cites] Eur J Biochem. 1995 Apr 15;229(2):558-65 [7744080.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):298-305 [15768047.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):283-93 [15866171.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2656-64 [16200199.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cancer Cell. 2005 Dec;8(6):443-54 [16338658.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Cell Metab. 2006 Jun;3(6):393-402 [16753575.001]
  • [Cites] Nat Protoc. 2006;1(1):241-5 [17406239.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):356-61 [18246068.001]
  • [Cites] Mol Cell. 2008 Mar 14;29(5):541-51 [18342602.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.17C [18432682.001]
  • [Cites] Science. 2008 Jun 13;320(5882):1496-501 [18497260.001]
  • [Cites] Sci Signal. 2008;1(43):pl3 [18957692.001]
  • [Cites] Cell Cycle. 2008 Nov 1;7(21):3355-61 [18948731.001]
  • [Cites] Cell Cycle. 2008 Nov 1;7(21):3344-54 [18971624.001]
  • [Cites] Cell. 2009 May 29;137(5):873-86 [19446321.001]
  • [Cites] Science. 2009 Oct 2;326(5949):140-4 [19797661.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):699-704 [12172555.001]
  • [Cites] Diabetes. 2002 Oct;51(10):2877-85 [12351422.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):859-64 [12389032.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5203-7 [10792038.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4654-60 [10969820.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(19):7311-8 [10982848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12222-6 [11050244.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):255-62 [11089983.001]
  • [Cites] Anal Biochem. 2001 Jun 15;293(2):169-77 [11399029.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1097-110 [11602639.001]
  • [Cites] Nature. 2001 Dec 13;414(6865):813-20 [11742414.001]
  • [Cites] Cell Death Differ. 2002 Feb;9(2):99-100 [11840159.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4319-24 [11930000.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16510-9 [12609977.001]
  • [Cites] Curr Top Microbiol Immunol. 2004;279:259-70 [14560962.001]
  • (PMID = 20739737.001).
  • [ISSN] 1945-4589
  • [Journal-full-title] Aging
  • [ISO-abbreviation] Aging (Albany NY)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Culture Media, Serum-Free; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ribosomal Protein S6; 9G2MP84A8W / Deoxyglucose; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; EC 3.5.1.- / Sirtuin 1
  • [Other-IDs] NLM/ PMC2954040
  •  go-up   go-down


56. Liu B, Lin Y, Darwanto A, Song X, Xu G, Zhang K: Identification and characterization of propionylation at histone H3 lysine 23 in mammalian cells. J Biol Chem; 2009 Nov 20;284(47):32288-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, in vitro assays demonstrated that histone acetyltransferase p300 can catalyze H3 Lys(23) propionylation, whereas histone deacetylase Sir2 can remove this modification in the presence of NAD(+).

  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Metab. 2008 Feb;7(2):104-12 [18249170.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6697-714 [17934479.001]
  • [Cites] Annu Rev Med. 2008;59:267-80 [17937590.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):877-81 [18354397.001]
  • [Cites] J Proteome Res. 2009 Feb;8(2):900-6 [19113941.001]
  • [Cites] Blood. 2009 Jul 16;114(3):651-8 [19443658.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] Anal Biochem. 2002 Jul 15;306(2):259-69 [12123664.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):23-33 [12694723.001]
  • [Cites] Anal Biochem. 1985 Apr;146(1):173-9 [3993929.001]
  • [Cites] Immunol Cell Biol. 1992 Apr;70 ( Pt 2):97-105 [1356919.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9 [8643484.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1236-47 [9488438.001]
  • [Cites] J Immunol. 1998 Aug 1;161(3):1390-8 [9686602.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:501-7 [10384314.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1262-6 [15988529.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1017-24 [16921363.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):812-9 [17267393.001]
  • [Cites] Nature. 2007 May 24;447(7143):425-32 [17522676.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):30239-45 [17684016.001]
  • [Cites] Chembiochem. 2008 Mar 3;9(4):499-503 [18247445.001]
  • (PMID = 19801601.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.17 / propionate - CoA ligase; K3Z4F929H6 / Lysine
  • [Other-IDs] NLM/ PMC2781642
  •  go-up   go-down


57. Niethammer P, Kueh HY, Mitchison TJ: Spatial patterning of metabolism by mitochondria, oxygen, and energy sinks in a model cytoplasm. Curr Biol; 2008 Apr 22;18(8):586-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Restriction of oxygen supply to the edge of a drop mimicked distance to the surface of a single cell, or distance from a blood vessel in tissue.
  • We imaged a step-like increase of Nicotinamide adenine dinucleotide (NAD) reduction approximately 600 microm distant from the oxygen source.
  • Addition of Adenosine triphosphate (ATP)-consuming beads mimicked local energy sinks in the cell.
  • We imaged Deltapsi gradients with a decay length of approximately 50-300 microm around these beads, in the first visualization of an energy demand signaling gradient.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2007 Jun 18;177(6):1029-36 [17562787.001]
  • [Cites] J Cell Biol. 2007 Aug 27;178(5):749-55 [17709429.001]
  • [Cites] Biophys J. 2000 Apr;78(4):1657-64 [10733948.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Apr;278(4):C747-64 [10751324.001]
  • [Cites] Methods Enzymol. 2004;385:361-70 [15130749.001]
  • [Cites] Science. 1969 Dec 5;166(3910):1297-8 [5350329.001]
  • [Cites] Circ Res. 1977 Nov;41(5):606-15 [908108.001]
  • [Cites] J Biol Chem. 1972 Jan 10;247(1):188-92 [4401581.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 1):C663-75 [3010727.001]
  • [Cites] Dev Biol. 1989 Apr;132(2):512-23 [2538374.001]
  • [Cites] J Biol Chem. 1990 Sep 15;265(26):15392-402 [2394731.001]
  • [Cites] Annu Rev Biophys Biophys Chem. 1991;20:1-28 [1867711.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 2):H1676-80 [8184947.001]
  • [Cites] Nat Med. 1997 Feb;3(2):177-82 [9018236.001]
  • [Cites] J Exp Biol. 1997 Jan;200(Pt 2):381-6 [9050247.001]
  • [Cites] Methods Cell Biol. 1999;61:385-412 [9891325.001]
  • [Cites] J Cell Sci. 2005 Dec 1;118(Pt 23):5411-9 [16306220.001]
  • [Cites] Exp Physiol. 2006 Sep;91(5):807-19 [16857720.001]
  • [Cites] Biochem Biophys Res Commun. 1985 Dec 31;133(3):1035-41 [4084301.001]
  • [Cites] Curr Top Dev Biol. 2006;76:217-57 [17118268.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):913-23 [17158952.001]
  • (PMID = 18406136.001).
  • [ISSN] 0960-9822
  • [Journal-full-title] Current biology : CB
  • [ISO-abbreviation] Curr. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM039565-21; United States / NIGMS NIH HHS / GM / R01 GM039565; United States / NIGMS NIH HHS / GM / R01 GM039565-21
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0U46U6E8UK / NAD; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS208661; NLM/ PMC2902971
  •  go-up   go-down


58. Maestre E, Katakis I, Narváez A, Domínguez E: A multianalyte flow electrochemical cell: application to the simultaneous determination of carbohydrates based on bioelectrocatalytic detection. Biosens Bioelectron; 2005 Nov 15;21(5):774-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the enzymatic sensors are mediated with different osmium compounds appropriate for each enzyme's mechanism (NAD or PQQ dehydrogenases) in some cases combining multienzyme sensors.
  • Cross referenced calibration curves were used for signal treatment and interpretation and it was possible to analyse real juice and milk samples with results agreeing with the standard enzymatic methods for the same analyses with a sampling frequency of more than 100 h(-1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16242617.001).
  • [ISSN] 0956-5663
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbohydrates; 0 / Complex Mixtures; 0 / Enzymes, Immobilized; EC 1.1.1.47 / Glucose 1-Dehydrogenase
  •  go-up   go-down


59. Shabalin IG, Filippova EV, Polyakov KM, Sadykhov EG, Safonova TN, Tikhonova TV, Tishkov VI, Popov VO: Structures of the apo and holo forms of formate dehydrogenase from the bacterium Moraxella sp. C-1: towards understanding the mechanism of the closure of the interdomain cleft. Acta Crystallogr D Biol Crystallogr; 2009 Dec;65(Pt 12):1315-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NAD(+)-dependent formate dehydrogenase (FDH) catalyzes the oxidation of formate ion to carbon dioxide coupled with the reduction of NAD(+) to NADH.
  • Apo MorFDH has a closed conformation of the interdomain cleft, which is unique for an apo form of an NAD(+)-dependent dehydrogenase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966418.001).
  • [ISSN] 1399-0047
  • [Journal-full-title] Acta crystallographica. Section D, Biological crystallography
  • [ISO-abbreviation] Acta Crystallogr. D Biol. Crystallogr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoenzymes; 0 / Holoenzymes; EC 1.2.1.2 / Formate Dehydrogenases
  •  go-up   go-down


60. Celebi JT, Ward KM, Wanner M, Polsky D, Kopf AW: Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol; 2005 Jan;30(1):68-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome.
  • Atypical mole syndrome is a sporadic or an inherited condition with an increased risk of melanoma.
  • In this study, we evaluated genes associated with familial and sporadic melanoma for mutations in 28 probands with the atypical mole syndrome.
  • These data suggest that genes evaluated in this study are unlikely to be candidate genes for atypical mole syndrome and support the notion that unknown susceptibility gene/s for this disease exist.
  • [MeSH-major] Dysplastic Nevus Syndrome / genetics. Germ-Line Mutation / genetics. Melanoma / genetics. Middle Aged. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663508.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


61. Grammel H, Ghosh R: Redox-state dynamics of ubiquinone-10 imply cooperative regulation of photosynthetic membrane expression in Rhodospirillum rubrum. J Bacteriol; 2008 Jul;190(14):4912-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results show that changes in the photosynthetic membrane levels between 50 and 95% of that maximally attainable are associated with only a twofold change in the ubiquinol/ubiquinone ratio and are not necessarily proportional to the total levels of either quinone or [NAD(+) + NADH].
  • [MeSH-minor] Aerobiosis. Bacterial Proteins / analysis. Chromatography, High Pressure Liquid. Light-Harvesting Protein Complexes / analysis. Mass Spectrometry. NAD / analysis. NADP / analysis. Oxidation-Reduction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Aug 15;19(16):4237-47 [10944106.001]
  • [Cites] Science. 2001 Jun 22;292(5525):2314-6 [11423658.001]
  • [Cites] Phytochemistry. 2003 Mar;62(6):929-37 [12590120.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4699-708 [12970182.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6577-86 [14602616.001]
  • [Cites] Nature. 2003 Nov 27;426(6965):460-5 [14647386.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):263-79 [15187184.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13318-23 [15326287.001]
  • [Cites] Biochem J. 1965 Sep;96(3):688-92 [5862408.001]
  • [Cites] Arch Mikrobiol. 1971;79(2):147-63 [4399577.001]
  • [Cites] Biochim Biophys Acta. 1979 Apr 11;546(1):1-16 [221012.001]
  • [Cites] Eur J Biochem. 1982 Jan;121(2):343-7 [6800786.001]
  • [Cites] Microbiol Rev. 1988 Mar;52(1):50-69 [3280966.001]
  • [Cites] J Bacteriol. 1998 Aug;180(16):4044-50 [9696749.001]
  • [Cites] J Bacteriol. 1999 Apr;181(8):2351-7 [10197995.001]
  • [Cites] Biochim Biophys Acta. 1965 Mar 22;96:395-428 [14314381.001]
  • [Cites] Biochim Biophys Acta. 1962 Jul 30;62:167-70 [14042348.001]
  • [Cites] J Gen Microbiol. 1960 Jun;22:778-85 [14447230.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6768-75 [16407278.001]
  • [Cites] Microbiology. 2007 Jun;153(Pt 6):1974-80 [17526854.001]
  • [Cites] J Bacteriol. 2007 Aug;189(15):5617-25 [17557830.001]
  • (PMID = 18487324.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Light-Harvesting Protein Complexes; 0U46U6E8UK / NAD; 1339-63-5 / Ubiquinone; 53-59-8 / NADP; I7T5V2W47R / Ubiquinone Q2; M9NL0C577Y / ubiquinol
  • [Other-IDs] NLM/ PMC2446998
  •  go-up   go-down


62. Albeniz I, Demir O, Türker-Sener L, Yalçintepe L, Nurten R, Bermek E: Erythrocyte CD38 as a prognostic marker in cancer. Hematology; 2007 Oct;12(5):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Erythrocyte NAD glycohydrolase and ADP-ribosyl cyclase activities in normal individuals and cancer patients were compared and correlation of these activities to CEA values and anemia were determined.
  • RESULTS: Erythrocyte NAD glycohydrolase and ADP-ribosyl cyclase activities were significantly increased in cancer, in parallel to enhancement of CD38 expression and in correlation with CEA values and anemia.
  • [MeSH-major] ADP-ribosyl Cyclase / analysis. Antigens, CD38 / analysis. Erythrocytes / chemistry. NAD+ Nucleosidase / analysis. Neoplasms / diagnosis
  • [MeSH-minor] Anemia / diagnosis. Anemia / etiology. Biomarkers / analysis. Case-Control Studies. Disease Progression. Humans. Neoplasm Proteins / analysis. Prognosis. Up-Regulation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852458.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Neoplasm Proteins; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / NAD+ Nucleosidase
  •  go-up   go-down


63. Onal C, Topkan E, Efe E, Yavuz M, Arslan G, Yavuz A: The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer. Br J Radiol; 2009 Dec;82(984):1019-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study cohort was divided into two groups depending on the duration of neoadjuvant androgen deprivation (NAD): 23 patients (44.7%) were designated as "short NAD" (< or =3 months;.
  • SNAD) and the remaining 29 (55.3%) as "long NAD" (>3 months; LNAD).
  • In conclusion, a higher prostate volume reduction during 3D-CRT was demonstrated when RT planning was performed within 3 months of NAD.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):655-60 [10837948.001]
  • [Cites] Br J Urol. 1995 Apr;75(4):492-7 [7788262.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):685-98 [11172950.001]
  • [Cites] Radiology. 2001 Feb;218(2):365-74 [11161148.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46 [11240234.001]
  • [Cites] Br J Radiol. 2001 Mar;74(879):243-8 [11338100.001]
  • [Cites] J Urol. 2001 Aug;166(2):500-6; discussion 506-7 [11458055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 [11483335.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] Radiother Oncol. 2003 Feb;66(2):151-7 [12648786.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1009-17 [7493827.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1311-20 [7493856.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1321-9 [7493857.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):333-42 [8635941.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1013-21 [9060541.001]
  • [Cites] Urology. 1997 Mar;49(3A Suppl):38-45 [9123735.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):931-9 [9276357.001]
  • [Cites] Radiother Oncol. 1998 Jun;47(3):285-92 [9681892.001]
  • [Cites] Radiother Oncol. 1998 Jun;47(3):293-6 [9681893.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):661-72 [9806528.001]
  • [Cites] Radiother Oncol. 2005 Feb;74(2):177-85 [15734206.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):567-72 [15762358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):625-34 [16343802.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):276-82 [16546279.001]
  • [Cites] J Natl Med Assoc. 2006 Jul;98(7):1058-61 [16895273.001]
  • [Cites] Radiother Oncol. 2007 May;83(2):163-7 [17499871.001]
  • [Cites] Radiother Oncol. 2009 Mar;90(3):312-7 [18783839.001]
  • [Cites] Radiother Oncol. 2009 Mar;90(3):285-90 [19038468.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1904-11 [12743142.001]
  • [Cites] Br J Urol. 1992 May;69(5):521-4 [1535824.001]
  • [Cites] Prostate. 1994 May;24(5):252-6 [8170838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):755-61 [8040021.001]
  • [Cites] Cancer Invest. 1995;13(1):8-15 [7834477.001]
  • [Cites] Urology. 1995 Apr;45(4):616-23 [7716842.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):195-200 [11054523.001]
  • (PMID = 19581310.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; A0Z3NAU9DP / bicalutamide
  • [Other-IDs] NLM/ PMC3473383
  •  go-up   go-down


64. Sung JY, Lee YN: Isoforms of glucose 6-phosphate dehydrogenase in Deinococcus radiophilus. J Microbiol; 2007 Aug;45(4):318-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucose 6-phosphate dehydrogenase (G6PDH, EC 1.1.1.49) in Deinococcus radiophilus, an extraordinarily UV-resistant bacterium, was investigated to gain insight into its resistance as it was shown to be involved in a scavenging system of superoxide (O2-1) and peroxide (O2-2) generated by UV and oxidative stresses. D. radiophilus possesses two G6PDH isoforms: G6PDH-1 and G6PDH-2, both showing dual coenzyme specificity for NAD and NADP.
  • The purified G6PDH-1 and G6PDH-2 had the specific activity of 2,890 and 1,033 U/mg protein (using NADP as cofactor) and 3,078 and 1,076 U/mg protein (using NAD as cofactor), respectively.
  • [MeSH-minor] Adenosine Triphosphate / pharmacology. Catalysis / drug effects. Electrophoresis, Polyacrylamide Gel. Hydrogen-Ion Concentration. Isoelectric Focusing. Isoenzymes / chemistry. Isoenzymes / isolation & purification. Isoenzymes / metabolism. Molecular Weight. Oleic Acid / pharmacology. Oxidative Stress. Superoxides / pharmacology. Temperature

  • Hazardous Substances Data Bank. OLEIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846585.001).
  • [ISSN] 1225-8873
  • [Journal-full-title] Journal of microbiology (Seoul, Korea)
  • [ISO-abbreviation] J. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Isoenzymes; 11062-77-4 / Superoxides; 12030-88-5 / potassium superoxide; 2UMI9U37CP / Oleic Acid; 8L70Q75FXE / Adenosine Triphosphate; EC 1.1.1.49 / Glucosephosphate Dehydrogenase
  •  go-up   go-down


65. Sharma BK, Smith CC, Laing JM, Rucker DA, Burnett JW, Aurelian L: Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions. Dermatology; 2006;213(3):192-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine whether H11 is silenced by aberrant DNA methylation in melanoma as compared to nevi and normal skin tissues.
  • METHODS: Cell suspensions from benign intradermal nevi, atypical nevi and malignant melanoma tissues were used in reverse-transcriptase PCR and methylation-specific PCR.
  • RESULTS: H11 is methylated in 60-75% of melanoma and atypical nevi, but not in normal skin or most benign nevi.
  • CONCLUSION: The heat shock protein H11 is silenced by aberrant DNA methylation in melanoma, but not benign melanocytic lesions or normal skin melanocytes.
  • [MeSH-major] DNA Methylation. Heat-Shock Proteins / genetics. Melanocytes / pathology. Melanoma / genetics. Protein-Serine-Threonine Kinases / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Apoptosis. Dysplastic Nevus Syndrome / genetics. Dysplastic Nevus Syndrome / metabolism. Dysplastic Nevus Syndrome / pathology. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Nevus, Intradermal / genetics. Nevus, Intradermal / metabolism. Nevus, Intradermal / pathology. Nevus, Pigmented / genetics. Nevus, Pigmented / metabolism. Nevus, Pigmented / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033167.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR-42647; United States / NIEHS NIH HHS / ES / ES07263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Heat-Shock Proteins; EC 2.7.1.- / HSPB8 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


66. Spallarossa P, Altieri P, Pronzato P, Aloi C, Ghigliotti G, Barsotti A, Brunelli C: Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane. J Pharmacol Exp Ther; 2010 Jan;332(1):87-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ErbB2 expression levels, AKT activation, and the effects of the inhibition of nicotinamide adenine dinucleotide phosphate oxidase [NAD(P)H oxidase] and phosphoinositide-3-OH kinase (PI3K) were also assessed.
  • Data demonstrate that 1) the toxic effects of epirubicin mainly occur through NAD(P)H oxidase activation;.
  • 2) the erbB2 overexpression induced by epirubicin is a redox-sensitive mechanism largely dependent on NAD(P)H oxidase;.
  • Data underline the importance of NAD(P)H oxidase in epirubicin-induced cardiotoxicity and shed new light on the protective mechanisms of dexrazoxane.

  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841470.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Cardiotonic Agents; 0 / Erbb2 protein, rat; 0 / Glycoproteins; 3Z8479ZZ5X / Epirubicin; 5AR83PR647 / Razoxane; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


67. Xu S, He Y, Vokurkova M, Touyz RM: Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension; 2009 Aug;54(2):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a coculture system we tested whether ECs modulate VSMC redox status by regulating activity of NAD(P)H oxidase and antioxidants.
  • NAD(P)H oxidase subunit expression and oxidase activity were determined by Western blotting and chemiluminescence, respectively.
  • In cocultured conditions, VSMC ROS production was reduced by approximately 50% without changes in NAD(P)H oxidase expression/activity versus monoculture (P<0.05).
  • The modulatory actions of ECs are independent of NOS/NO, Cox2, and HETE and do not involve NAD(P)H oxidase.


68. Hisahara S, Chiba S, Matsumoto H, Horio Y: Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRT1 (Sir2alpha). J Pharmacol Sci; 2005 Jul;98(3):200-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRT1 (Sir2alpha).
  • Sir2 (silent information regulator 2) is an NAD-dependent deacetylase that is broadly conserved from bacteria to humans.
  • It catalyzes a unique deacetylation reaction using NAD, and specific inhibitors and activators of its activity have been discovered.
  • [MeSH-minor] Animals. Basic Helix-Loop-Helix Transcription Factors. DNA-Binding Proteins / physiology. Forkhead Transcription Factors. Hepatocyte Nuclear Factor 3-gamma. Humans. NAD / metabolism. Nuclear Proteins / physiology. Signal Transduction. Sirtuin 1. Transcription Factors / physiology. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006743.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / FOXA3 protein, human; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Nuclear Proteins; 0 / Transcription Factors; 0U46U6E8UK / NAD; 135845-91-9 / Hepatocyte Nuclear Factor 3-gamma; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; EC 3.5.1.98 / Histone Deacetylases
  • [Number-of-references] 41
  •  go-up   go-down


69. Skwara P, Mach T, Tomaszewska R, Sobczyk-Krupiarz I, Cieśla A: [Studies on relationship between immunodeficiency in HIV-infected people and condition of upper gastrointestinal tract mucosa, prevalence of mycosis and Helicobacter pylori infection]. Przegl Lek; 2005;62(12):1401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Badania nad zaleznościa upośledzenia odporności u osób zakazonych HIV a stanem błony sluzowej górnego odcinka przewodu pokarmowego, wystepowaniem grzybicy i infekcji Helicobacter pylori.


70. Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, Ltaief A, Bennamou S, Limem K: Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol; 2009;62(6):349-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The objective of this study was to investigate the usefulness of CSF Abeta1-42 and T-tau analyses in the diagnosis of AD with Tunisians.
  • METHODS: We focused on three groups originating from Central Tunisian that matched in age (range 48-85): healthy controls (n = 53), AD patients (n = 93) and non-Alzheimer (nAD) dementia (n = 35) patients.
  • RESULTS: The ratio of T-tau/Abeta1-42 at baseline yielded a sensitivity of 85.3% for detection of AD and the specificity was 84.8% to differentiate controls and nAD dementia.
  • [MeSH-major] Alzheimer Disease / diagnosis. Amyloid beta-Peptides / cerebrospinal fluid. Peptide Fragments / cerebrospinal fluid. tau Proteins / cerebrospinal fluid
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Biomarkers / cerebrospinal fluid. Chi-Square Distribution. Cognition Disorders / cerebrospinal fluid. Cognition Disorders / diagnosis. Diagnosis, Differential. Diagnostic and Statistical Manual of Mental Disorders. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Phosphorylation. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Alzheimer Disease.
  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786779.001).
  • [ISSN] 1421-9913
  • [Journal-full-title] European neurology
  • [ISO-abbreviation] Eur. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Biomarkers; 0 / Peptide Fragments; 0 / amyloid beta-protein (1-42); 0 / tau Proteins
  •  go-up   go-down


71. Khan MI, Ito K, Kim H, Ashida H, Ishikawa T, Shibata H, Sawa Y: Molecular properties and enhancement of thermostability by random mutagenesis of glutamate dehydrogenase from Bacillus subtilis. Biosci Biotechnol Biochem; 2005 Oct;69(10):1861-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recombinant Bs-GluDH was purified to homogeneity and has been determined to have a hexameric structure (M(r) 270 kDa) with strict specificity for 2-oxoglutarate and L-glutamate, requiring NADH and NAD+ as cofactors respectively.
  • [MeSH-minor] Cloning, Molecular. Dimerization. Enzyme Stability. Glutamic Acid / metabolism. Hot Temperature. Ketoglutaric Acids / metabolism. Kinetics. Molecular Weight. Mutation, Missense. NAD. Substrate Specificity / genetics

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244435.001).
  • [ISSN] 0916-8451
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ketoglutaric Acids; 0U46U6E8UK / NAD; 328-50-7 / alpha-ketoglutaric acid; 3KX376GY7L / Glutamic Acid; EC 1.4.1.2 / Glutamate Dehydrogenase
  •  go-up   go-down


72. Scope A, Busam KJ, Malvehy J, Puig S, McClain SA, Braun RP, Marghoob AA: Ex vivo dermoscopy of melanocytic tumors: time for dermatopathologists to learn dermoscopy. Arch Dermatol; 2007 Dec;143(12):1548-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have identified cases of skin cancer with discordances between clinical, dermoscopic, and histopathologic findings that were likely due to sampling errors in the pathology laboratory.
  • OBSERVATIONS: The orientation of the lesion, overall dermoscopic pattern, and dermoscopic pigmented structures (network, globules, and peripheral streaks) were readily correlated between the in vivo and ex vivo images for 2 melanomas and 4 dysplastic nevi.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Dermoscopy. Dysplastic Nevus Syndrome / pathology. Melanocytes / pathology. Melanoma / pathology. Skin Neoplasms / pathology


73. Holbourn KP, Shone CC, Acharya KR: A family of killer toxins. Exploring the mechanism of ADP-ribosylating toxins. FEBS J; 2006 Oct;273(20):4579-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ADP-ribosylating toxins (ADPRTs) are a family of toxins that catalyse the hydrolysis of NAD and the transfer of the ADP-ribose moiety onto a target.
  • This family includes many notorious killers, responsible for thousands of deaths annually including: cholera, enterotoxic Escherichia coli, whooping cough, diphtheria and a plethora of Clostridial binary toxins.
  • They all share a common fold and several motifs around the active site that collectively facilitate the binding and transfer of the ADP-ribose moiety of NAD to their protein targets.
  • [MeSH-minor] Amino Acid Motifs. Amino Acid Sequence. Binding Sites. Conserved Sequence. Models, Molecular. Molecular Sequence Data. NAD / metabolism. Sequence Alignment

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956368.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Toxins, Biological; 0U46U6E8UK / NAD; EC 2.4.2.- / ADP Ribose Transferases
  • [Number-of-references] 88
  •  go-up   go-down


74. Ma B, Pan SJ, Zupancic ML, Cormack BP: Assimilation of NAD(+) precursors in Candida glabrata. Mol Microbiol; 2007 Oct;66(1):14-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assimilation of NAD(+) precursors in Candida glabrata.
  • The yeast pathogen Candida glabrata is a nicotinamide adenine dinucleotide (NAD(+)) auxotroph and its growth depends on the environmental supply of vitamin precursors of NAD(+). C. glabrata salvage pathways defined in this article allow NAD(+) to be synthesized from three compounds - nicotinic acid (NA), nicotinamide (NAM) and nicotinamide riboside (NR).
  • The second is a novel pathway in which NR is degraded by the nucleosidases Pnp1 and Urh1, with a minor role for Meu1, and ultimately converted to NAD(+) via the nicotinamidase Pnc1 and the Preiss-Handler pathway.
  • Using C. glabrata mutants whose growth depends exclusively on the external NA or NR supply, we also show that C. glabrata utilizes NR and to a lesser extent NA as NAD(+) sources during disseminated infection.
  • [MeSH-major] Candida glabrata / metabolism. Metabolic Networks and Pathways. NAD / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725566.001).
  • [ISSN] 0950-382X
  • [Journal-full-title] Molecular microbiology
  • [ISO-abbreviation] Mol. Microbiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 2P01DK49720; United States / NIAID NIH HHS / AI / 5R01AI046223-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0U46U6E8UK / NAD; 1341-23-7 / nicotinamide-beta-riboside; 25X51I8RD4 / Niacinamide; 2679MF687A / Niacin; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / nicotinamide riboside kinase; EC 3.2.2.- / N-Glycosyl Hydrolases; EC 3.5.1.19 / Nicotinamidase
  •  go-up   go-down


75. Dasgupta BR, Antharavally BS, Tepp W, Evenson ML: Botulinum neurotoxin types A, B, and E: fragmentations by autoproteolysis and other mechanisms including by O-phenanthroline-dithiothreitol, and association of the dinucleotides NAD(+)/NADH with the heavy chain of the three neurotoxins. Protein J; 2005 Aug;24(6):337-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Botulinum neurotoxin types A, B, and E: fragmentations by autoproteolysis and other mechanisms including by O-phenanthroline-dithiothreitol, and association of the dinucleotides NAD(+)/NADH with the heavy chain of the three neurotoxins.
  • The first evidence of autoproteolytic activity of the approximately 50-kDa light chain of the clostridial neurotoxins (NT) is traceable to the observations that the light chains of botulinum NT serotypes A and E, separated from their approximately 100-kDa heavy chain conjugate, were found cleaved at the amino side of Tyr250 and Arg244, respectively [DasGupta and Foley (1989).
  • None of the identified cleaved bonds (-P1-P1' -) in one serotype (except Asp-Pro) was found common in other serotypes or cleaved within itself at a second site.
  • After separation from the heavy chain self-cleavages of the light chains of type A, B and E at Tyr249-Tyr250, Gln258-Ser259 and Ile243-Arg244, respectively indicate an intriguing feature (in the aligned sequences these bonds of type A and B are 2 and type A and E are 4 peptide bonds apart) that may have some role in the NT's structure-function relationship yet to be understood.
  • We point out that autoproteolysis of a single peptide bond (Phe418-Thr419 or Phe422-Glu423) in NT type A reported by Ahmed et al. (2001) can potentially generate proteolytically active light chain freed of the heavy chain; this is an efficient pathway, that by-passes nicking by a trypsin-like protease(s) inside the intrachain disulfide bridge and its reductive cleavage.
  • The metal chelator O-phenanthroline (above critical miceller concentration) in the presence of dithiothreitol cleaved type E NT at limited sites generating discrete 114-, 87-, 49-, 42-, and 31-kDa fragments but degraded NTs type A and B extensively.
  • The dinucleotide NAD(+)/NADH associated with the NTs type A, B and E (2-3 NADH per protein molecule) via their H-chains, and a portion of the H-chain (toward the C-terminus) appears to exhibit limited amino acid sequence homology with lactate dehydrogenase-a representative NAD(+)/NADH binding protein.
  • [MeSH-minor] Amino Acid Sequence. Botulinum Toxins, Type A / metabolism. Dithiothreitol. L-Lactate Dehydrogenase / chemistry. Molecular Weight. NAD / metabolism. Peptide Hydrolases / metabolism. Phenanthrolines. Sequence Homology, Amino Acid

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicon. 1983;21(4):535-45 [6353669.001]
  • [Cites] Nat Struct Biol. 1998 Oct;5(10):898-902 [9783750.001]
  • [Cites] J Mol Biol. 1999 Jul 2;290(1):37-48 [10388556.001]
  • [Cites] J Gen Microbiol. 1986 Jul;132(7):1981-8 [2432159.001]
  • [Cites] Biochem J. 1992 Jul 1;285 ( Pt 1):9-12 [1637325.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18322-5 [8702470.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Toxicon. 2001 Oct;39(10 ):1515-31 [11478959.001]
  • [Cites] FEBS Lett. 1996 May 20;386(2-3):133-6 [8647267.001]
  • [Cites] J Biol Chem. 1985 Sep 5;260(19):10461-6 [4030755.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):339-42 [9224685.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14721-9 [1634516.001]
  • [Cites] Anal Biochem. 1989 Nov 15;183(1):108-21 [2619035.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):415-6 [7984234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3208-13 [14982988.001]
  • [Cites] Biochem J. 1997 Mar 1;322 ( Pt 2):507-10 [9065770.001]
  • [Cites] J Mol Biol. 1999 Sep 3;291(5):1091-104 [10518945.001]
  • [Cites] Arch Biochem Biophys. 1984 Jul;232(1):172-8 [6430237.001]
  • [Cites] FEBS Lett. 1997 Nov 24;418(1-2):1-5 [9414082.001]
  • [Cites] Biochimie. 1989 Nov-Dec;71(11-12):1193-200 [2517479.001]
  • [Cites] J Physiol (Paris). 1990;84(3):220-8 [2074545.001]
  • [Cites] Methods Enzymol. 1985;117:346-54 [4079809.001]
  • [Cites] Toxicon. 1980;18(5-6):705-10 [7222076.001]
  • [Cites] J Protein Chem. 2001 Apr;20(3):221-31 [11565902.001]
  • [Cites] Nat Struct Biol. 2003 Jan;10(1):13-8 [12459720.001]
  • [Cites] Infect Immun. 2003 Mar;71(3):1147-54 [12595426.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2660-3 [3029090.001]
  • [Cites] FASEB J. 1996 Sep;10(11):1257-69 [8836039.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3459-64 [9013591.001]
  • [Cites] Eur J Biochem. 1992 Mar 1;204(2):657-67 [1541280.001]
  • [Cites] Arch Biochem Biophys. 1988 Oct;266(1):142-51 [3178218.001]
  • [Cites] Can J Microbiol. 1968 Jul;14(7):805-7 [4879302.001]
  • [Cites] Biochemistry. 2004 Mar 2;43(8):2209-16 [14979717.001]
  • [Cites] J Biol Chem. 1992 May 5;267(13):9053-8 [1577743.001]
  • [Cites] FEBS Lett. 1998 Jun 5;429(1):78-82 [9657387.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1992 Feb;345(2):227-34 [1570025.001]
  • [Cites] Infect Immun. 1989 Oct;57(10):3053-7 [2506129.001]
  • [Cites] Biochemistry. 2003 Nov 4;42(43):12539-49 [14580200.001]
  • [Cites] Biochemistry. 1998 Apr 14;37(15):5267-78 [9548758.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20353-8 [8702770.001]
  • [Cites] Toxicon. 2001 Feb-Mar;39(2-3):233-43 [10978741.001]
  • [Cites] J Neurochem. 1999 Jan;72 (1):327-37 [9886085.001]
  • [Cites] Protein Sci. 1999 Mar;8(3):518-28 [10091654.001]
  • [Cites] J Protein Chem. 1997 Oct;16(7):701-12 [9330228.001]
  • [Cites] J Cell Biol. 2003 Sep 29;162(7):1293-303 [14504267.001]
  • [Cites] J Protein Chem. 1998 Apr;17 (3):187-96 [9588942.001]
  • [Cites] J Protein Chem. 1998 Jul;17(5):417-28 [9717738.001]
  • [Cites] FEBS Lett. 2002 Dec 18;532(3):423-6 [12482605.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1316-21 [12552129.001]
  • [Cites] J Biol Chem. 1995 May 5;270(18):10566-70 [7737992.001]
  • [Cites] Toxicon. 1988;26(9):817-25 [3201486.001]
  • [Cites] J Biol Chem. 1987 Jul 25;262(21):10035-8 [3611052.001]
  • [Cites] Nat Struct Biol. 2000 Aug;7(8):693-9 [10932256.001]
  • [Cites] Clin Med (Lond). 2004 May-Jun;4(3):258-61 [15244362.001]
  • [Cites] Anal Biochem. 1986 Jul;156(1):213-9 [3740411.001]
  • [Cites] Biochimie. 2000 May;82(5):427-46 [10865130.001]
  • [Cites] Biochimie. 1990 Sep;72(9):661-4 [2126206.001]
  • [Cites] Toxicon. 1984;22(3):415-24 [6382680.001]
  • [Cites] Methods Enzymol. 1973;27:441-55 [4773289.001]
  • [Cites] Biochim Biophys Acta. 1962 Oct 8;63:530-2 [13955687.001]
  • (PMID = 16323041.001).
  • [ISSN] 1572-3887
  • [Journal-full-title] The protein journal
  • [ISO-abbreviation] Protein J.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS17742; United States / NINDS NIH HHS / NS / NS24545
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Phenanthrolines; 0U46U6E8UK / NAD; 0Y70779M1F / rimabotulinumtoxinB; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.- / Peptide Hydrolases; EC 3.4.24.69 / Botulinum Toxins; EC 3.4.24.69 / Botulinum Toxins, Type A; T579M564JY / botulinum toxin type E; T8ID5YZU6Y / Dithiothreitol; W4X6ZO7939 / 1,10-phenanthroline
  •  go-up   go-down


76. Lukacik P, Keller B, Bunkoczi G, Kavanagh KL, Lee WH, Adamski J, Oppermann U: Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. Biochem J; 2007 Mar 15;402(3):419-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro, DHRS10 converts NAD+ into NADH in the presence of oestradiol, testosterone and 5-androstene-3beta,17beta-diol.
  • Furthermore, the product of oestradiol oxidation, oestrone, was identified in intact cells transfected with a construct plasmid encoding the DHRS10 protein.
  • It also reveals a broad and deep active site cleft into which NAD+ and oestradiol can be docked in a catalytically competent orientation.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49 [11165022.001]
  • [Cites] Chem Biol Interact. 2001 Jan 30;130-132(1-3):499-525 [11306071.001]
  • [Cites] Chem Biol Interact. 2001 Jan 30;130-132(1-3):699-705 [11306087.001]
  • [Cites] Curr Opin Chem Biol. 2001 Aug;5(4):375-82 [11470599.001]
  • [Cites] Eur J Biochem. 2001 Aug;268(15):4113-25 [11488903.001]
  • [Cites] Comb Chem High Throughput Screen. 2001 Nov;4(7):545-52 [11669066.001]
  • [Cites] Endocrinol Metab Clin North Am. 2002 Mar;31(1):63-78 [12055991.001]
  • [Cites] Sci STKE. 2002 Jun 25;2002(138):pe29 [12084905.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25677-84 [11976334.001]
  • [Cites] Eur J Neurosci. 2002 Aug;16(3):445-53 [12193187.001]
  • [Cites] Eur J Biochem. 2002 Sep;269(18):4409-17 [12230552.001]
  • [Cites] J Neurosci. 2002 Oct 1;22(19):8391-401 [12351713.001]
  • [Cites] J Neurochem. 2002 Nov;83(3):713-26 [12390533.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4984-90 [12414862.001]
  • [Cites] J Biol Chem. 2003 Jan 17;278(3):2030-5 [12397058.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D255-7 [14681406.001]
  • [Cites] Obes Res. 2004 Jan;12(1):9-17 [14742837.001]
  • [Cites] Recent Prog Horm Res. 2004;59:359-93 [14749510.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):432-8 [14993666.001]
  • [Cites] Synapse. 2000 Jan;35(1):39-44 [10579806.001]
  • [Cites] Hepatology. 2000 Apr;31(4):990-6 [10733557.001]
  • [Cites] Methods Enzymol. 2000;316:372-83 [10800688.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24333-40 [10811639.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2000 Aug;56(Pt 8):965-72 [10944333.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):1-4 [11165003.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):7-20 [15130507.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2711-6 [15181046.001]
  • [Cites] Mol Neurobiol. 1988 Fall;2(3):183-200 [3077066.001]
  • [Cites] Rev Neurosci. 1994 Jan-Mar;5(1):27-41 [8019704.001]
  • [Cites] Biochem J. 1994 Dec 15;304 ( Pt 3):787-92 [7818482.001]
  • [Cites] Biochemistry. 1995 May 9;34(18):6003-13 [7742302.001]
  • [Cites] Biochem J. 1996 Mar 15;314 ( Pt 3):839-45 [8615778.001]
  • [Cites] Structure. 1996 Aug 15;4(8):905-15 [8805577.001]
  • [Cites] J Mol Biol. 1997 May 9;268(3):678-85 [9171291.001]
  • [Cites] Genomics. 1997 Nov 15;46(1):112-9 [9403065.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1319-24 [9543162.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21 [9757107.001]
  • [Cites] Anat Embryol (Berl). 1999 May;199(5):379-90 [10221449.001]
  • [Cites] Exp Gerontol. 2004 Nov-Dec;39(11-12):1579-86 [15582272.001]
  • [Cites] Semin Reprod Med. 2005 May;23(2):172-9 [15852203.001]
  • [Cites] Endocr Rev. 2005 May;26(3):308-12 [15851820.001]
  • [Cites] J Neurobiol. 2005 Jul;64(1):34-46 [15884004.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):287-301 [16181121.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):61-71 [16414178.001]
  • [ErratumIn] Biochem J. 2007 May 1;403(3):615. Kavanagh, Kathryn [Kavanagh, Kathryn L]; Hwa, Lee Wen [corrected to Lee, Wen Hwa]
  • (PMID = 17067289.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ligands; 0U46U6E8UK / NAD; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.1.- / HSD17B14 protein, human
  • [Other-IDs] NLM/ PMC1863559
  •  go-up   go-down


77. Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R, Labandeira-Garcia JL: Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging; 2007 Apr;28(4):555-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiotensin II activates (via type 1 receptors) NAD(P)H-dependent oxidases, which are a major source of superoxide, and is relevant in the pathogenesis of several cardiovascular diseases and certain degenerative changes associated with ageing.
  • Dopaminergic degeneration was also reduced by the NAD(P)H inhibitor apocynin.

  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621167.001).
  • [ISSN] 1558-1497
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic Agents; 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Naphthyridines; 0 / Thiobarbituric Acid Reactive Substances; 0 / ZD 7155; 8HW4YBZ748 / Oxidopamine; EC 1.14.16.2 / Tyrosine 3-Monooxygenase; VTD58H1Z2X / Dopamine
  •  go-up   go-down


78. Dhawan AP, D'Alessandro B, Patwardhan S, Mullani N: Multispectral optical imaging of skin-lesions for detection of malignant melanomas. Conf Proc IEEE Eng Med Biol Soc; 2009;2009:5352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multispectral optical imaging of skin-lesions for detection of malignant melanomas.
  • Optical imaging of skin-lesions for early detection and management of the most fatal skin-cancer malignant melanoma is of significant interest in mass screening of skin-lesions with high-risk population.
  • Surface illumination based optical imaging methods such as epiluminescence light microscopy (ELM) through "Dermascopy" has shown a significant potential in improving early diagnosis of malignant melanomas.
  • We have developed a novel optical imaging system, the Nevoscope, that uses multispectral transillumination as to provide images of skin-lesions showing sub-surface pigmentation as well as vascular architecture based blood volume information.
  • This paper presents multispectral Nevoscope transillumination method to compare and analyze ratiometric measurements to epiluminescence imaging for its ability to discriminate malignant melanomas from dysplastic nevi and other normal skin-lesions.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis. Transillumination / instrumentation. Transillumination / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19964673.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, Doerries C, Horváth T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U: Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation; 2007 Jul 10;116(2):163-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small-interfering RNA silencing of NAD(P)H oxidase subunit p47(phox) reduced superoxide production and restored NO bioavailability and in vivo reendothelialization capacity of EPCs from diabetic patients.
  • Importantly, rosiglitazone therapy normalized NAD(P)H oxidase activity, restored NO bioavailability, and improved in vivo reendothelialization capacity of EPCs from diabetic patients (reendothelialized area: placebo versus rosiglitazone, 8+/-1% versus 38+/-5%; P<0.001).
  • CONCLUSIONS: In vivo reendothelialization capacity of EPCs derived from individuals with diabetes mellitus is severely impaired at least partially as a result of increased NAD(P)H oxidase-dependent superoxide production and subsequently reduced NO bioavailability.
  • Rosiglitazone therapy reduces NAD(P)H oxidase activity and improves reendothelialization capacity of EPCs from diabetic individuals, representing a potential novel mechanism whereby peroxisome proliferator-activated receptor-gamma agonism promotes vascular repair.


80. Izzicupo P, Di Valerio V, D' Amico MA, Di Mauro M, Pennelli A, Falone S, Alberti G, Amicarelli F, Miscia S, Gallina S, Di Baldassarre A: NAD(P)H oxidase and pro-inflammatory response during maximal exercise: role of C242T polymorphism of the P22PHOX subunit. Int J Immunopathol Pharmacol; 2010 Jan-Mar;23(1):203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD(P)H oxidase and pro-inflammatory response during maximal exercise: role of C242T polymorphism of the P22PHOX subunit.
  • Intense exercise induces a pro-inflammatory status through a mechanism involving the NAD(P)H oxidase system.
  • We focused our attention on p22phox, a subunit of the NAD(P)H oxidase, and on its allelic polymorphism C242T, which is known to affect the functional activity of the enzyme.
  • In addition, the presence of T allele was associated with a higher cardiopulmonary efficiency as evidenced by a significantly lower Heart Rate (HR) at the peak of exercise and, when a dominant model was assumed, by a higher maximal oxygen uptake (VO2 max).
  • These results contribute to support the hypothesis of a systemic effect for the C242T polymorphism and of its possible functional rebound in healthy subjects.

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378006.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; EC 1.11.1.7 / Peroxidase; EC 1.6.3.1 / CYBA protein, human; EC 1.6.3.1 / NADPH Oxidase; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


81. Chen R, Chen JY, Zhou LW: Metabolic patterns (NAD(P)H) in rat basophilic leukemia (RBL-2H3) cells and human hepatocellular carcinoma (Hep G2) cells with autofluorescence imaging. Ultrastruct Pathol; 2008 Sep-Oct;32(5):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic patterns (NAD(P)H) in rat basophilic leukemia (RBL-2H3) cells and human hepatocellular carcinoma (Hep G2) cells with autofluorescence imaging.
  • Although the spatial and temporal distributions of cellular NAD(P)H concentrations have been theoretically predicted as typical patterns of the metabolism in living cells, so far such a pattern was observed only in neutrophils.
  • In this work, the dynamic NAD(P)H distributions in rat basophilic leukemia (RBL-2H3) and human hepatocellular carcinoma (Hep G2) cells were studied by imaging the autofluorescence of cellular NAD(P)H with a sensitive CCD detector in a confocal microscope.
  • The typical pattern of the cytoplasmic NAD(P)H wave traveling along the long axis of the elongated cell with a velocity of 2.2+/-0.6 mircom/s was detected in RBL-2H3 cells.
  • While in the case of Hep G2 cells, only the oscillation of the mitochondrial NAD(P)H was observed because the NAD(P)H mainly localized in mitochondria of Hep G2 cells.
  • These results confirm the metabolic pattern of NAD(P)H in living cells and suggest that the expression of the metabolic pattern probably differs in different cell lines.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958792.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 53-59-8 / NADP
  •  go-up   go-down


82. Horenstein AL, Sizzano F, Lusso R, Besso FG, Ferrero E, Deaglio S, Corno F, Malavasi F: CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol Med; 2009 Mar-Apr;15(3-4):76-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nicotinamide adenine dinucleotide (NAD(+)), a precursor of molecules involved in cell regulatory processes, is released in extra-cellular compartments after stress or inflammation.This study investigates the expression in the human cornea of CD38 and CD157, two NAD(+)-consuming ectoenzymes and surface receptors.
  • The presence of enzymatically active NAD(+)-consumers in intact corneal cells was analyzed by high performance liquid chromatography (HPLC)-based assays.
  • The results of the work indicates that the human cornea is equipped with molecular tools capable of consuming extracellular NAD(+), and that CD157 is a potential marker of corneal limbal cells in the stem cell niche.
  • [MeSH-minor] Biomarkers / metabolism. Cornea / anatomy & histology. Cornea / metabolism. GPI-Linked Proteins. Humans. NAD / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 2004 Sep;88(9):1154-8 [15317707.001]
  • [Cites] Stem Cells. 2004;22(3):355-66 [15153612.001]
  • [Cites] Cell. 1989 Apr 21;57(2):201-9 [2702690.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 May;34(6):1983-90 [7684031.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Aug;34(9):2672-9 [8344790.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Nov 15;196(3):1459-65 [8250903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5325-9 [8202488.001]
  • [Cites] J Immunol. 1994 Aug 1;153(3):952-9 [7913116.001]
  • [Cites] J Biol Chem. 1994 Dec 2;269(48):30260-7 [7982936.001]
  • [Cites] FEBS Lett. 1994 Dec 19;356(2-3):244-8 [7805847.001]
  • [Cites] J Immunol. 1996 Jan 15;156(2):727-34 [8543826.001]
  • [Cites] J Biol Chem. 1996 Jul 5;271(27):15922-7 [8663150.001]
  • [Cites] Int Immunol. 1996 Nov;8(11):1643-50 [8943558.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Apr 28;233(3):801-5 [9168937.001]
  • [Cites] Protein Expr Purif. 1998 Feb;12(1):133-7 [9473467.001]
  • [Cites] Biochem J. 1998 Mar 15;330 ( Pt 3):1129-35 [9494077.001]
  • [Cites] Brain Res. 1999 Mar 6;821(1):17-25 [10064783.001]
  • [Cites] J Cell Biol. 1999 May 17;145(4):769-82 [10330405.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1957-65 [15914609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9523-8 [15983386.001]
  • [Cites] Methods Mol Biol. 2005;308:191-208 [16082036.001]
  • [Cites] Clin Experiment Ophthalmol. 2006 Jan-Feb;34(1):64-73 [16451261.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4295-301 [17003418.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5032-8 [17065524.001]
  • [Cites] Semin Cell Dev Biol. 2006 Dec;17(6):654-66 [17178241.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Mar;48(3):978-84 [17325135.001]
  • [Cites] Mol Med. 2006 Nov-Dec;12(11-12):317-23 [17380198.001]
  • [Cites] Mol Med. 2006 Nov-Dec;12(11-12):334-41 [17380201.001]
  • [Cites] Antioxid Redox Signal. 2008 Feb;10(2):179-206 [18020963.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):841-86 [18626062.001]
  • [Cites] FASEB J. 2001 Jan;15(1):10-12 [11099492.001]
  • [Cites] Tissue Antigens. 2000 Dec;56(6):539-47 [11169244.001]
  • [Cites] Diabetes. 2001 May;50(5):985-91 [11334442.001]
  • [Cites] Glia. 2002 Sep;39(3):314-9 [12203397.001]
  • [Cites] Cell Biochem Funct. 2002 Dec;20(4):309-22 [12415565.001]
  • [Cites] Eur J Biochem. 2004 Mar;271(5):1025-34 [15009214.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Exp Eye Res. 2004 Mar;78(3):433-46 [15106923.001]
  • [Cites] Hum Immunol. 1984 Jan;9(1):9-20 [6693298.001]
  • (PMID = 19052657.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Grant] Italy / Telethon / / GTF06004
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / GPI-Linked Proteins; 0U46U6E8UK / NAD; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / ADP-ribosyl cyclase 2; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


83. Slominska EM, Yuen A, Osman L, Gebicki J, Yacoub MH, Smolenski RT: Cytoprotective effects of nicotinamide derivatives in endothelial cells. Nucleosides Nucleotides Nucleic Acids; 2008 Jun;27(6):863-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoprotective effects of nicotinamide derivatives in endothelial cells.
  • Following discovery of NAD(+)-dependent reactions that control gene expression, cytoprotection, and longevity, there has been a renewed therapeutic interest in precursors, such as nicotinamide and its derivatives.
  • We tested 20 analogues of nicotinamide for their ability to protect endothelial cells from peroxynitrite stress and their effect on poly (ADP-ribose) polymerase (PARP) activity.
  • Several nicotinamide derivatives protected endothelial cells from peroxynitrite-induced depletion of cellular NAD(+) and ATP concentrations, but only some of these compounds inhibited PARP.
  • We conclude that some nicotinamide derivatives provide protection of endothelial cells against peroxynitrite-induced injury independent of inhibition of PARP activity.
  • Preservation of the NAD(+) pool was a common effect of these compounds.
  • [MeSH-minor] Cell Line. Humans. NAD / metabolism. Poly(ADP-ribose) Polymerase Inhibitors. Time Factors

  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18600553.001).
  • [ISSN] 1532-2335
  • [Journal-full-title] Nucleosides, nucleotides & nucleic acids
  • [ISO-abbreviation] Nucleosides Nucleotides Nucleic Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0U46U6E8UK / NAD; 25X51I8RD4 / Niacinamide
  •  go-up   go-down


84. Bychkov PV, Shekhovtsova TN, Milaeva ER: Inhibition of horse liver alcohol dehydrogenase by methyltin compounds. Bioinorg Chem Appl; 2005;:191-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data acquired on NAD-dependent ADH from horse liver and those regarding NAD-dependent LDH from sturgeon liver were compared.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365099.001).
  • [ISSN] 1565-3633
  • [Journal-full-title] Bioinorganic chemistry and applications
  • [ISO-abbreviation] Bioinorg Chem Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2267099
  • [Keywords] NOTNLM ; NAD / alcohol dehydrogenase / inhibition type / methyltin compounds
  •  go-up   go-down


85. Brimfield AA, Novak MJ, Hodgson E: Thiodiglycol, the hydrolysis product of sulfur mustard: analysis of in vitro biotransformation by mammalian alcohol dehydrogenases using nuclear magnetic resonance. Toxicol Appl Pharmacol; 2006 Jun 15;213(3):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intermediate nature of this mixture was determined spectrophotometrically when it was shown to drive the production of NADH when added to ADH and NAD.

  • Hazardous Substances Data Bank. THIODIGLYCOL .
  • Hazardous Substances Data Bank. BIS(2-CHLOROETHYL)SULFIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417912.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Sulfhydryl Compounds; 9BW5T43J04 / 2,2'-thiodiethanol; EC 1.1.1.1 / Alcohol Dehydrogenase; T8KEC9FH9P / Mustard Gas
  •  go-up   go-down


86. Lebe B, Pabuççuoglu U, Ozer E: Expression pattern of type IV collagen in sporadic dysplastic melanocytic nevi. Anal Quant Cytol Histol; 2008 Oct;30(5):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of type IV collagen in sporadic dysplastic melanocytic nevi.
  • OBJECTIVE: To investigate the expression and distribution pattern of type IV collagen in dysplastic nevi (DN) and to determine whether DN exhibits a morphologic difference from common melanocytic nevi (CMN) and cutaneous malignant melanomas (MM) and therefore can be classified as a separate entity.
  • STUDY DESIGN: We examined 33 DN specimens, 18 CMN specimens, and 10 MM specimens.
  • Twenty-one of 33 DN showed a continuous pattern of type IV collagen surrounding junctional nests in a concentric fashion while a discontinuous immunostaining pattern was observed in remaining cases.
  • The expression pattern of type IV collagen in DN was statistically different from CMN and MM.
  • CONCLUSION: Our results suggest sporadic DN is biologically different from CMN in terms of the capacity to synthesize type IV collagen, demonstrating that DN is not only morphologically but also biologically a different entity from CMN.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980161.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV
  •  go-up   go-down


87. Barranco WT, Kim DH, Stella SL Jr, Eckhert CD: Boric acid inhibits stored Ca2+ release in DU-145 prostate cancer cells. Cell Biol Toxicol; 2009 Aug;25(4):309-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we report that boric acid (BA) inhibits NAD+ and NADP+ as well as mechanically induced release of stored Ca2+ in growing DU-145 prostate cancer cells.
  • NAD+-induced Ca2+ transients were partly inhibited at 250 microM BA and completely at 1,000 microM BA, whereas both NADP+ and mechanically induced transients were inhibited by 1,000 microM BA.
  • In vitro mass spectrometry analysis showed that BA formed adducts with the CD38 products and Ca2+ channel agonists cyclic adenosine diphosphate ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP).
  • The BA analog, methylboronic acid (MBA; 250 and 1,000 microM), did not inhibit cell proliferation or NAD+, NADP+, or mechanically stimulated Ca2+ store release.
  • [MeSH-minor] Antigens, CD38 / metabolism. Calcium Signaling / drug effects. Cell Line, Tumor. Cyclic ADP-Ribose / metabolism. Humans. Male. NAD / metabolism. NADP / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516691.001).
  • [ISSN] 1573-6822
  • [Journal-full-title] Cell biology and toxicology
  • [ISO-abbreviation] Cell Biol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Boric Acids; 0U46U6E8UK / NAD; 119340-53-3 / Cyclic ADP-Ribose; 53-59-8 / NADP; EC 3.2.2.5 / Antigens, CD38; R57ZHV85D4 / boric acid; SY7Q814VUP / Calcium
  •  go-up   go-down


88. Casalino E, Calzaretti G, Landriscina M, Sblano C, Fabiano A, Landriscina C: The Nrf2 transcription factor contributes to the induction of alpha-class GST isoenzymes in liver of acute cadmium or manganese intoxicated rats: comparison with the toxic effect on NAD(P)H:quinone reductase. Toxicology; 2007 Jul 31;237(1-3):24-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Nrf2 transcription factor contributes to the induction of alpha-class GST isoenzymes in liver of acute cadmium or manganese intoxicated rats: comparison with the toxic effect on NAD(P)H:quinone reductase.
  • The stimulation is associated with a higher level of alpha-class GST proteins, whose induction is blocked by actinomycin D co-administration.
  • For comparison, we have evaluated the status of another important antioxidant enzyme, NAD(P)H:quinone reductase, 24h after cadmium or manganese administration.
  • [MeSH-major] Cadmium Chloride / toxicity. Chlorides / toxicity. Glutathione Transferase / biosynthesis. Isoenzymes / biosynthesis. Liver. NAD(P)H Dehydrogenase (Quinone) / biosynthesis. NF-E2 Transcription Factor, p45 Subunit / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MANGANESE COMPOUNDS .
  • Hazardous Substances Data Bank. CADMIUM CHLORIDE .
  • Hazardous Substances Data Bank. MANGANESE CHLORIDE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573173.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chlorides; 0 / Enzyme Inhibitors; 0 / Isoenzymes; 0 / Manganese Compounds; 0 / NF-E2 Transcription Factor, p45 Subunit; 99Z2744345 / Ditiocarb; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, rat; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha; H6241UJ22B / Selenium; J6K4F9V3BA / Cadmium Chloride; QQE170PANO / manganese chloride
  •  go-up   go-down


89. Diani-Moore S, Ram P, Li X, Mondal P, Youn DY, Sauve AA, Rifkind AB: Identification of the aryl hydrocarbon receptor target gene TiPARP as a mediator of suppression of hepatic gluconeogenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin and of nicotinamide as a corrective agent for this effect. J Biol Chem; 2010 Dec 10;285(50):38801-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the aryl hydrocarbon receptor target gene TiPARP as a mediator of suppression of hepatic gluconeogenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin and of nicotinamide as a corrective agent for this effect.
  • TCDD suppressed hepatic glucose production, expression of key gluconeogenic genes, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase), and NAD(+) levels, and increased PARP activity and TiPARP expression.
  • TiPARP overexpression reproduced TCDD effects on glucose output and NAD(+) levels whereas TiPARP silencing diminished them.
  • The vitamin B3 constituent, nicotinamide (NAM), prevented TCDD suppression of glucose output, NAD(+), and gluconeogenic genes and stabilized PGC1α.
  • The corrective effects of NAM could be attributed to increased NAD(+) levels and suppression of AHR target gene induction.

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuromolecular Med. 2009;11(1):28-42 [19288225.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(1):30-9 [17954562.001]
  • [Cites] Endocr Rev. 2010 Apr;31(2):194-223 [20007326.001]
  • [Cites] Oncogene. 2010 Aug 19;29(33):4617-24 [20531298.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:519-61 [10836146.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):131-8 [11557972.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 30;289(2):499-506 [11716501.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Arch Biochem Biophys. 2002 Aug 15;404(2):309-16 [12147270.001]
  • [Cites] Chem Biol Interact. 2002 Sep 20;141(1-2):131-60 [12213389.001]
  • [Cites] Hum Gene Ther. 2002 Sep 1;13(13):1561-70 [12228011.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1843-55 [12612060.001]
  • [Cites] Biochemistry. 2003 Aug 12;42(31):9249-56 [12899610.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1982;22:517-54 [6282188.001]
  • [Cites] Toxicol Lett. 1985 Jun;25(3):247-58 [4012802.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 14;174(3):1267-71 [1996990.001]
  • [Cites] Toxicology. 1991 Feb;66(2):133-44 [1849669.001]
  • [Cites] Arch Toxicol Suppl. 1992;15:151-5 [1510582.001]
  • [Cites] Toxicology. 1993 Mar 30;79(1):81-95 [8475501.001]
  • [Cites] Mol Pharmacol. 1993 Dec;44(6):1142-51 [8264550.001]
  • [Cites] Arch Toxicol. 1994;69(2):73-8 [7717864.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Sep;140(1):173-9 [8806883.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):33054-9 [8955152.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50754-63 [15381699.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):361-70 [16054085.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):10684-94 [16314495.001]
  • [Cites] Mol Pharmacol. 2006 Jan;69(1):140-53 [16214954.001]
  • [Cites] Toxicol Sci. 2006 Mar;90(1):96-110 [16330490.001]
  • [Cites] Drug Metab Rev. 2006;38(1-2):291-335 [16684662.001]
  • [Cites] Annu Rev Biochem. 2006;75:435-65 [16756498.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19000-8 [16670093.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28 [16829982.001]
  • [Cites] J Biochem Mol Toxicol. 2006;20(4):151-8 [16906519.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Dec 15;217(3):363-74 [17109908.001]
  • [Cites] J Med Chem. 2007 Dec 27;50(26):6458-61 [18052316.001]
  • [Cites] Chem Res Toxicol. 2008 Jan;21(1):102-16 [18076143.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Jan 1;234(1):1-13 [18948129.001]
  • [Cites] Anal Biochem. 2009 Feb 15;385(2):377-9 [19027704.001]
  • [Cites] AAPS J. 2006;8(4):E632-43 [17233528.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Mar;23(2):164-70 [17268245.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):562-6 [17392787.001]
  • [Cites] Toxicol Sci. 2007 Jul;98(1):5-38 [17569696.001]
  • [Cites] Toxicol Lett. 2007 Aug10;172(3):146-58 [17669606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11288-93 [19549853.001]
  • (PMID = 20876576.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA062948; United States / NCI NIH HHS / CA / T32-CA062948; United States / NIDDK NIH HHS / DK / R01-DK73466; United States / NIEHS NIH HHS / ES / R01 ES003606; United States / NIEHS NIH HHS / ES / R01-ES03606; United States / NIDDK NIH HHS / DK / R01 DK073466; United States / NCI NIH HHS / CB / N02-CB-666000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; 0 / Transcription Factors; 0U46U6E8UK / NAD; 25X51I8RD4 / Niacinamide; 9005-79-2 / Glycogen; DO80M48B6O / Tetrachlorodibenzodioxin; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2998137
  •  go-up   go-down


90. Wojnowski W, Obrebowski A, Pruszewicz A, Demenko G, Wiskirska-Woźnica B, Swidziński P: [Further research on speech tests]. Otolaryngol Pol; 2007;61(6):979-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Dalsze badania nad testami mowy utrudnionej.
  • [MeSH-major] Audiometry, Speech. Hearing Disorders / diagnosis. Noise

  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • MedlinePlus Health Information. consumer health - Noise.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546946.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


91. Chan KM, Rajab NF, Siegel D, Din LB, Ross D, Inayat-Hussain SH: Goniothalamin induces coronary artery smooth muscle cells apoptosis: the p53-dependent caspase-2 activation pathway. Toxicol Sci; 2010 Aug;116(2):533-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the p53 elevation in GN-treated CASMCs was independent of NAD(P)H: quinone oxidoreductase 1 and Mdm-2 expression.
  • [MeSH-minor] Adenosine Triphosphate / analysis. Amino Acid Chloromethyl Ketones / pharmacology. Cells, Cultured. Cytochromes c / secretion. Dose-Response Relationship, Drug. Enzyme Activation. Humans. Hydrogen Peroxide / metabolism. Membrane Potential, Mitochondrial / drug effects. NAD(P)H Dehydrogenase (Quinone) / metabolism. Oxygen Consumption / drug effects. Superoxides / metabolism

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20498002.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Pyrones; 0 / Tumor Suppressor Protein p53; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 11062-77-4 / Superoxides; 34W9GO6B2Z / goniothalamin; 8L70Q75FXE / Adenosine Triphosphate; 9007-43-6 / Cytochromes c; BBX060AN9V / Hydrogen Peroxide; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 3.4.22.- / Caspase 2
  •  go-up   go-down


92. Xiao T, Shoeb M, Siddiqui MS, Zhang M, Ramana KV, Srivastava SK, Vasiliou V, Ansari NH: Molecular cloning and oxidative modification of human lens ALDH1A1: implication in impaired detoxification of lipid aldehydes. J Toxicol Environ Health A; 2009;72(9):577-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purified recombinant human lens ALDH1A1 exhibited optimal catalytic activity at pH 8 and preferred NAD(+) as cofactor and specifically catalyzed the oxidation of toxic lipid aldehydes such as 4-hydroxynonenal (HNE; K(m) = 4.8 microM) and malonaldehyde (K(m) MDA = 3.5 microM).
  • Further, modification of recombinant human lens ALDH1A1 with nitric oxide donors such as S-nitroso-N-acetylpenicillamine (SNAP) and S-nitrosoglutathione (GSNO) significantly inhibited the enzyme activity.

  • MedlinePlus Health Information. consumer health - Cataract.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1980 Nov 7;620(2):281-96 [6254573.001]
  • [Cites] Mol Aspects Med. 2003 Aug-Oct;24(4-5):167-75 [12892994.001]
  • [Cites] Genome Res. 1996 Sep;6(9):791-806 [8889548.001]
  • [Cites] Enzyme. 1991;45(4):188-93 [1823864.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2675-82 [12766072.001]
  • [Cites] Eur J Biochem. 1999 Jun;262(3):704-12 [10411631.001]
  • [Cites] Biochem Mol Med. 1996 Jun;58(1):25-30 [8809342.001]
  • [Cites] J Biochem. 2000 Nov;128(5):771-6 [11056389.001]
  • [Cites] Biochem Pharmacol. 1991 Jun 1;41(11):1583-7 [2043148.001]
  • [Cites] Arch Ophthalmol. 2005 Aug;123(8):1102-5 [16087845.001]
  • [Cites] Biochem J. 2003 Dec 15;376(Pt 3):615-23 [12943535.001]
  • [Cites] Chem Biol Interact. 2001 Jan 30;130-132(1-3):261-73 [11306050.001]
  • [Cites] Free Radic Biol Med. 1991;11(1):81-128 [1937131.001]
  • [Cites] Pharmacogenetics. 1999 Aug;9(4):421-34 [10780262.001]
  • [Cites] Biochem Pharmacol. 1998 Jun 15;55(12 ):2007-15 [9714321.001]
  • [Cites] Biochim Biophys Acta. 1996 Dec 6;1291(3):182-8 [8980630.001]
  • [Cites] Mol Aspects Med. 2003 Aug-Oct;24(4-5):149-59 [12892992.001]
  • [Cites] Chem Biol Interact. 2001 Jan 30;130-132(1-3):57-69 [11306031.001]
  • [Cites] Structure. 1998 Dec 15;6(12):1541-51 [9862807.001]
  • [Cites] Bull World Health Organ. 2004 Nov;82(11):844-51 [15640920.001]
  • [Cites] DNA Cell Biol. 2003 May;22(5):329-38 [12941160.001]
  • [Cites] Biochem Pharmacol. 1985 Apr 15;34(8):1197-204 [3994742.001]
  • [Cites] Ophthalmologica. 2001 Mar-Apr;215(2):113-6 [11244341.001]
  • [Cites] Biochemistry. 1997 Dec 16;36(50):15801-9 [9398310.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(11):3771-5 [2987944.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13748-54 [9354647.001]
  • [Cites] J Biol Chem. 1984 Oct 10;259(19):11986-90 [6480593.001]
  • [Cites] J Biol Chem. 2007 Aug 31;282(35):25668-76 [17567582.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Aug;17(4):828-31 [8214422.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jan;46(1):259-67 [15623782.001]
  • [Cites] Lens Eye Toxic Res. 1990;7(2):161-71 [2275929.001]
  • [Cites] Arch Ophthalmol. 1993 Aug;111(8):1041-9 [8352686.001]
  • [Cites] FASEB J. 1995 Sep;9(12):1173-82 [7672510.001]
  • [Cites] FASEB J. 2003 Mar;17(3):417-25 [12631581.001]
  • [Cites] Semin Cell Dev Biol. 2008 Apr;19(2):100-12 [18077195.001]
  • [Cites] Curr Eye Res. 2001 Oct;23(4):307-11 [11852433.001]
  • [Cites] J Exp Zool. 1998 Sep-Oct 1;282(1-2):12-7 [9723161.001]
  • [Cites] J Cataract Refract Surg. 2002 Mar;28(3):507-12 [11973099.001]
  • [Cites] Gene. 1997 Jun 3;191(2):167-72 [9218716.001]
  • [Cites] Biochem J. 1978 Sep 1;173(3):787-98 [30447.001]
  • [Cites] Free Radic Biol Med. 2000 Oct 1;29(7):642-51 [11033416.001]
  • (PMID = 19296407.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / R29 EY011490; United States / NEI NIH HHS / EY / R01 EY013014; United States / NEI NIH HHS / EY / EY13014; United States / NEI NIH HHS / EY / R01 EY011490; United States / NEI NIH HHS / EY / EY11490; United States / NIDDK NIH HHS / DK / R37 DK036118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 1.2.1.3 / ALDH1A1 protein, human; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


93. Rathbone CR, Booth FW, Lees SJ: Sirt1 increases skeletal muscle precursor cell proliferation. Eur J Cell Biol; 2009 Jan;88(1):35-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over-expression of the NAD+-dependent histone deacetylase Sirt1 increased MPC proliferation and cell cycle progression as evidenced by increased 5-bromo-2'-deoxyuridine (BrdU) incorporation, an increase in cell number, proliferating cell nuclear antigen expression, and the phosphorylation of retinoblastoma protein.
  • Using O2 levels as a platform to modulate basal Sirt1 protein, activation of Sirt1 activity with resveratrol in 20% O2 increased MPC proliferation while inhibition of Sirt1 with nicotinamide in 5% O2 lowered proliferation.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2003 Jul;12(1):51-62 [12887892.001]
  • [Cites] Science. 2003 Nov 28;302(5650):1575-7 [14645852.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2011-5 [14976264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10042-7 [15220471.001]
  • [Cites] Cell Prolif. 2004 Aug;37(4):267-77 [15245563.001]
  • [Cites] Exp Cell Res. 1986 Sep;166(1):209-19 [2874992.001]
  • [Cites] Cell. 1992 Oct 30;71(3):505-14 [1358458.001]
  • [Cites] Cell Prolif. 2008 Apr;41(2):193-207 [18336467.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):588-603 [7913900.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Nature. 1994 Jun 16;369(6481):574-8 [7911228.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7060-9 [9003781.001]
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] Methods Cell Biol. 1997;52:155-76 [9379949.001]
  • [Cites] Ann N Y Acad Sci. 1998 Nov 20;854:78-91 [9928422.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):760-4 [15716955.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12339-43 [15713665.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Feb;290(2):C609-15 [16192302.001]
  • [Cites] Interdiscip Top Gerontol. 2007;35:137-58 [17063037.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E151-7 [16926381.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6823-32 [17197703.001]
  • [Cites] Biochem J. 2007 May 15;404(1):1-13 [17447894.001]
  • [Cites] Clin Nutr. 2007 Aug;26(4):389-99 [17499396.001]
  • [Cites] Ann Med. 2007;39(5):335-45 [17701476.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Acta Physiol Scand. 1999 Dec;167(4):301-5 [10632630.001]
  • [Cites] J Mol Med (Berl). 2003 Jun;81(6):355-62 [12732930.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2002 Oct;57(10):B359-65 [12242311.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Oct;283(4):C1182-95 [12225982.001]
  • [Cites] Biochem Mol Biol Int. 1995 May;36(1):59-66 [7545052.001]
  • (PMID = 18922599.001).
  • [ISSN] 1618-1298
  • [Journal-full-title] European journal of cell biology
  • [ISO-abbreviation] Eur. J. Cell Biol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG018780; United States / NIA NIH HHS / AG / AG18780; United States / NIAMS NIH HHS / AR / AR048523; United States / NIAMS NIH HHS / AR / T32 AR048523-05; None / None / / R01 AG018780-08; United States / NIAMS NIH HHS / AR / T32 AR048523; United States / NIA NIH HHS / AG / R01 AG018780-08; United States / NIAMS NIH HHS / AR / AR048523-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cyclin-Dependent Kinase Inhibitor p21; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.5.1.- / Sirt1 protein, mouse; EC 3.5.1.- / Sirt1 protein, rat; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS88690; NLM/ PMC2656762
  •  go-up   go-down


94. Lantsman Y, Tan KS, Morada M, Yarlett N: Biochemical characterization of a mitochondrial-like organelle from Blastocystis sp. subtype 7. Microbiology; 2008 Sep;154(Pt 9):2757-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical characterization of a mitochondrial-like organelle from Blastocystis sp. subtype 7.
  • Biochemical characterization enabled the demonstration of several key enzymes that allowed the construction of a metabolic pathway consisting of an incomplete Krebs cycle linked to the oxygen-sensitive enzymes pyruvate : NADP(+) oxidoreductase (PNO), acetate : succinate CoA transferase (ASCT) and succinate thiokinase (STK), which cumulatively are responsible for recycling CoA and generating ATP.
  • The organelle differs from typical aerobic mitochondria in possessing an oxygen-sensitive PNO that can use FAD(+) or FMN(+) as electron acceptor but is inactive with NAD(+), Spinacia oleracea ferredoxin or Clostridium pasteurianum ferredoxin.
  • A second cluster with 56 % sequence similarity to the pyruvate : ferredoxin oxidoreductase (PFOR) from Trichomonas vaginalis was also identified, which is in agreement with the concept that the PNO gene arose through the fusion of a eubacterial gene for PFOR with the gene for NADPH : cytochrome p450 reductase.
  • Based upon the results of this study, the Blastocystis organelle falls into the category of a MLO.
  • [MeSH-minor] Adenosine Triphosphate / biosynthesis. Animals. Citric Acid Cycle. Coenzyme A-Transferases / metabolism. Flavin Mononucleotide / metabolism. Flavin-Adenine Dinucleotide / metabolism. Ketone Oxidoreductases / metabolism. NAD / metabolism. Protozoan Proteins / metabolism. Succinate-CoA Ligases / metabolism

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18757809.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / NCDDG AI40320
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protozoan Proteins; 0U46U6E8UK / NAD; 146-14-5 / Flavin-Adenine Dinucleotide; 7N464URE7E / Flavin Mononucleotide; 8L70Q75FXE / Adenosine Triphosphate; EC 1.2.- / Ketone Oxidoreductases; EC 1.2.1.51 / pyruvate dehydrogenase (NADP+); EC 2.8.3.- / Coenzyme A-Transferases; EC 2.8.3.- / acetate-succinate CoA-transferase; EC 6.2.1.- / Succinate-CoA Ligases
  •  go-up   go-down


95. Deganuto M, Pittis MG, Pines A, Dominissini S, Kelley MR, Garcia R, Quadrifoglio F, Bembi B, Tell G: Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol; 2007 Jul;212(1):223-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gaucher disease (GD) is a lysosomal storage disorder, due to glucosylceramide (GlcCer) accumulation in several body tissues, which causes cellular failure by yet unidentified mechanisms.
  • The ROS rise is probably due to NAD(P)H oxidase activity, being inhibited by the treatment with diphenylene iodonium chloride.


96. de la Lastra CA, Villegas I, Sánchez-Fidalgo S: Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des; 2007;13(9):933-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poly(ADP-ribose) polymerase (PARP) comprise of a family of enzymes which catalyses poly(ADP-ribosyl)ation of DNA-binding proteins.
  • PARP-1, the best characterised member, works as a DNA damage nick-sensor protein that uses beta-NAD(+) to form polymers of ADP-ribose and has been implicated in DNA repair, maintenance of genomic integrity and mammalian longevity.
  • The generation of free radicals, reactive oxygen species, and peroxynitrite causes overactivation of PARP resulting in the depletion of NAD(+) and ATP and consequently in necrotic cell death and organ dysfunction.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430191.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Hypoglycemic Agents; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Protective Agents; 0 / Protein Subunits; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 375
  •  go-up   go-down


97. Grasberger H, De Deken X, Miot F, Pohlenz J, Refetoff S: Missense mutations of dual oxidase 2 (DUOX2) implicated in congenital hypothyroidism have impaired trafficking in cells reconstituted with DUOX2 maturation factor. Mol Endocrinol; 2007 Jun;21(6):1408-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dual oxidase 2 (DUOX2), a reduced NAD phosphate:O2 oxidoreductase flavoprotein, is a component of the thyrocyte H2O2 generator required for hormone synthesis at the apical plasma membrane.
  • D506N displays a partial deficiency phenotype with reduced surface expression of a mutant protein with normal intrinsic activity in generating H2O2.
  • DUOXA2 may thus be part of a secondary quality control system specific for DUOX2.

  • Genetic Alliance. consumer health - Congenital Hypothyroidism.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374849.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK15070; United States / NIDDK NIH HHS / DK / DK20595; United States / NCRR NIH HHS / RR / RR00055
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DUOXA2 protein, human; 0 / DUOXA2 protein, rat; 0 / Flavoproteins; 0 / Membrane Proteins; 0 / Polysaccharides; BBX060AN9V / Hydrogen Peroxide; EC 1.6.3.1 / DUOX2 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 3.2.1.96 / Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase
  •  go-up   go-down


98. Arita M, Oh SF, Chonan T, Hong S, Elangovan S, Sun YP, Uddin J, Petasis NA, Serhan CN: Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J Biol Chem; 2006 Aug 11;281(32):22847-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With NAD+ as a cofactor, recombinant 15-hydroxyprostaglandin dehydrogenase acted as an 18-hydroxyl dehydrogenase to form 18-oxo-RvE1.
  • At a concentration where RvE1 potently reduced polymorphonuclear leukocyte (PMN) recruitment in zymosan-induced peritonitis, 18-oxo-RvE1 was devoid of activity.
  • These results established the structure of a novel RvE1 initial metabolite, indicating that conversion of RvE1 to the oxo product represents a mode of RvE1 inactivation.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757471.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-074448; United States / NIDCR NIH HHS / DE / P50-DE-016191
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; 0 / Anti-Inflammatory Agents; 0 / Cytokines; 0 / Recombinant Proteins; AAN7QOV9EA / Eicosapentaenoic Acid; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase
  •  go-up   go-down


99. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M: Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol; 2006 Apr;26(4):917-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Production of superoxide anion and expression of NAD(P)H oxidase subunit p47phox, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 in the aorta were increased with the high-cholesterol diet.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424347.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccl2 protein, mouse; 0 / Chemokine CCL2; 0 / Cholesterol, Dietary; 0 / Tetrazoles; 0 / Tumor Necrosis Factor-alpha; 11062-77-4 / Superoxides; 27O7W4T232 / Spironolactone; 4964P6T9RB / Aldosterone; 6995V82D0B / eplerenone; 80M03YXJ7I / Valsartan; EC 1.6.3.1 / NADPH Oxidase; EC 1.6.3.1 / neutrophil cytosolic factor 1; HG18B9YRS7 / Valine
  •  go-up   go-down


100. Zhang Q, Hrmova M, Shirley NJ, Lahnstein J, Fincher GB: Gene expression patterns and catalytic properties of UDP-D-glucose 4-epimerases from barley (Hordeum vulgare L.). Biochem J; 2006 Feb 15;394(Pt 1):115-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterologous expression of a near full-length cDNA confirmed that HvUGE1 encodes a functional UGE.
  • A non-covalently bound NAD+ was released from the enzyme after denaturing with aqueous ethanol and was identified by its spectrophotometric properties and by electrospray ionization MS.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2003 May 22;19(8):1015-8 [12761065.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2003 Jan-Feb;25(1):41-3 [12690705.001]
  • [Cites] Gene. 2003 Nov 13;319:65-9 [14597172.001]
  • [Cites] Plant Physiol. 2004 Jan;134(1):224-36 [14701917.001]
  • [Cites] Curr Opin Plant Biol. 2004 Jun;7(3):277-84 [15134748.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22635-42 [15016816.001]
  • [Cites] Plant Physiol. 2004 Jul;135(3):1221-30 [15247385.001]
  • [Cites] Mol Genet Genomics. 2004 Aug;272(1):35-46 [15221451.001]
  • [Cites] Biochim Biophys Acta. 1973 Jun 20;313(1):72-94 [4745681.001]
  • [Cites] J Mol Biol. 1981 Mar 25;147(1):195-7 [7265238.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10774-8 [6885800.001]
  • [Cites] Nucleic Acids Res. 1984 Jan 11;12(1 Pt 1):387-95 [6546423.001]
  • [Cites] J Biol Chem. 1990 Jan 25;265(3):1319-26 [2153126.001]
  • [Cites] J Cell Biol. 1991 Feb;112(4):589-602 [1993733.001]
  • [Cites] Mol Microbiol. 1991 Jun;5(6):1519-30 [1787800.001]
  • [Cites] Proteins. 1992 Apr;12(4):372-81 [1579570.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] J Bacteriol. 1994 Jan;176(2):450-9 [7507102.001]
  • [Cites] Arch Biochem Biophys. 1996 Mar 1;327(1):27-34 [8615692.001]
  • [Cites] Biochemistry. 1997 Sep 2;36(35):10675-84 [9271498.001]
  • [Cites] Structure. 1997 Aug 15;5(8):1093-108 [9309224.001]
  • [Cites] Electrophoresis. 1997 Dec;18(15):2714-23 [9504803.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13597-602 [9811845.001]
  • [Cites] Plant Physiol. 2004 Dec;136(4):4256-64 [15563616.001]
  • [Cites] Plant Physiol. 2005 May;138(1):131-41 [15849307.001]
  • [Cites] Planta. 2005 Jun;221(4):538-48 [15655675.001]
  • [Cites] Biochemistry. 2000 May 16;39(19):5691-701 [10801319.001]
  • [Cites] Biol Chem. 2000 Aug;381(8):723-40 [11030430.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):143-9 [11308013.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15131-6 [11279032.001]
  • [Cites] Arch Biochem Biophys. 2001 Jul 15;391(2):188-96 [11437350.001]
  • [Cites] Plant Mol Biol. 2001 Sep;47(1-2):95-113 [11554483.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27528-34 [12019271.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32923-9 [12042319.001]
  • [Cites] Arch Biochem Biophys. 2002 Nov 15;407(2):209-16 [12413493.001]
  • [Cites] Curr Biol. 2002 Oct 29;12(21):1840-5 [12419184.001]
  • [Cites] Plant Cell. 2003 Feb;15(2):523-31 [12566589.001]
  • [Cites] Mol Biochem Parasitol. 2003 Feb;126(2):173-80 [12615316.001]
  • [Cites] Plant J. 2003 Sep;35(6):693-703 [12969423.001]
  • (PMID = 16266295.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY943954/ AY943955/ AY943956
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 5.1.3.- / Carbohydrate Epimerases
  • [Other-IDs] NLM/ PMC1386009
  •  go-up   go-down






Advertisement